<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Antigen‐specific active immunotherapy for ovarian cancer - Paijens, ST - 2018 | Cochrane Library</title> <meta content="Antigen‐specific active immunotherapy for ovarian cancer - Paijens, ST - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007287.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Antigen‐specific active immunotherapy for ovarian cancer - Paijens, ST - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007287.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007287.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Antigen‐specific active immunotherapy for ovarian cancer" name="citation_title"/> <meta content="Sterre T Paijens" name="citation_author"/> <meta content="University Medical Center Groningen (UMCG)" name="citation_author_institution"/> <meta content="s.t.paijens@umcg.nl" name="citation_author_email"/> <meta content="Ninke Leffers" name="citation_author"/> <meta content="University Medical Center Groningen (UMCG)" name="citation_author_institution"/> <meta content="Toos Daemen" name="citation_author"/> <meta content="University Medical Center Groningen (UMCG)" name="citation_author_institution"/> <meta content="Wijnand Helfrich" name="citation_author"/> <meta content="University Medical Center Groningen (UMCG)" name="citation_author_institution"/> <meta content="H Marike Boezen" name="citation_author"/> <meta content="University Medical Center Groningen (UMCG)" name="citation_author_institution"/> <meta content="Ben J Cohlen" name="citation_author"/> <meta content="Isala Clinics, Location Sophia" name="citation_author_institution"/> <meta content="Cornelis JM Melief" name="citation_author"/> <meta content="Leiden University Medical Center" name="citation_author_institution"/> <meta content="Marco de Bruyn" name="citation_author"/> <meta content="University Medical Center Groningen (UMCG)" name="citation_author_institution"/> <meta content="Hans W Nijman" name="citation_author"/> <meta content="University Medical Center Groningen (UMCG)" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD007287.pub4" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/09/10" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007287.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007287.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007287.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="CA-125 Antigen; *Immunotherapy, Active; *Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007287.pub4&amp;doi=10.1002/14651858.CD007287.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007287\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007287\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ms","fr","ko","hr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007287.pub4",title:"Antigen\\u2010specific active immunotherapy for ovarian cancer",firstPublishedDate:"Sep 10, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007287.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007287.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007287.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007287.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007287.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007287.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007287.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007287.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007287.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007287.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>2957 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007287.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-sec-0103"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-sec-0036"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-sec-0037"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-sec-0042"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-sec-0045"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-sec-0066"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-sec-0097"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/appendices#CD007287-sec-0107"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Antigen‐specific active immunotherapy for ovarian cancer</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sterre T Paijens</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0003">Ninke Leffers</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0004">Toos Daemen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0005">Wijnand Helfrich</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0006">H Marike Boezen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0007">Ben J Cohlen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0008">Cornelis JM Melief</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0009">Marco de Bruyn</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information#CD007287-cr-0010">Hans W Nijman</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information/en#CD007287-sec-0115">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 10 September 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007287.pub4">https://doi.org/10.1002/14651858.CD007287.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007287-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007287-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007287-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007287-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007287-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007287-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007287-abs-0015">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007287-abs-0001" lang="en"> <section id="CD007287-sec-0001"> <h3 class="title" id="CD007287-sec-0001">Background</h3> <p>This is the second update of the review first published in the Cochrane Library (2010, Issue 2) and later updated (2014, Issue 9). </p> <p>Despite advances in chemotherapy, the prognosis of ovarian cancer remains poor. Antigen‐specific active immunotherapy aims to induce tumour antigen‐specific anti‐tumour immune responses as an alternative treatment for ovarian cancer. </p> </section> <section id="CD007287-sec-0002"> <h3 class="title" id="CD007287-sec-0002">Objectives</h3> <p><i><b>Primary objective</b> </i><br/> • To assess the clinical efficacy of antigen‐specific active immunotherapy for the treatment of ovarian cancer as evaluated by tumour response measured by Response Evaluation Criteria In Solid Tumors (RECIST) and/or cancer antigen (CA)‐125 levels, response to post‐immunotherapy treatment, and survival differences </p> <p>◦ In addition, we recorded the numbers of observed antigen‐specific humoral and cellular responses<br/> <i><b>Secondary objective</b> </i><br/> • To establish which combinations of immunotherapeutic strategies with tumour antigens provide the best immunological and clinical results </p> </section> <section id="CD007287-sec-0003"> <h3 class="title" id="CD007287-sec-0003">Search methods</h3> <p>For the previous version of this review, we performed a systematic search of the Cochrane Central Register of Controlled Trials (CENTRAL; 2009, Issue 3), in the Cochrane Library, the Cochrane Gynaecological Cancer Group Specialised Register, MEDLINE and Embase databases, and clinicaltrials.gov (1966 to July 2009). We also conducted handsearches of the proceedings of relevant annual meetings (1996 to July 2009). </p> <p>For the first update of this review, we extended the searches to October 2013, and for this update, we extended the searches to July 2017. </p> </section> <section id="CD007287-sec-0004"> <h3 class="title" id="CD007287-sec-0004">Selection criteria</h3> <p>We searched for randomised controlled trials (RCTs), as well as non‐randomised studies (NRSs), that included participants with epithelial ovarian cancer, irrespective of disease stage, who were treated with antigen‐specific active immunotherapy, irrespective of type of vaccine, antigen used, adjuvant used, route of vaccination, treatment schedule, and reported clinical or immunological outcomes. </p> </section> <section id="CD007287-sec-0005"> <h3 class="title" id="CD007287-sec-0005">Data collection and analysis</h3> <p>Two reviews authors independently extracted the data. We evaluated the risk of bias for RCTs according to standard methodological procedures expected by Cochrane, and for NRSs by using a selection of quality domains deemed best applicable to the NRS. </p> </section> <section id="CD007287-sec-0006"> <h3 class="title" id="CD007287-sec-0006">Main results</h3> <p>We included 67 studies (representing 3632 women with epithelial ovarian cancer). The most striking observations of this review address the lack of uniformity in conduct and reporting of early‐phase immunotherapy studies. Response definitions show substantial variation between trials, which makes comparison of trial results unreliable. Information on adverse events is frequently limited. Furthermore, reports of both RCTs and NRSs frequently lack the relevant information necessary for risk of bias assessment. Therefore, we cannot rule out serious biases in most of the included trials. However, selection, attrition, and selective reporting biases are likely to have affected the studies included in this review. GRADE ratings were high only for survival; for other primary outcomes, GRADE ratings were very low. </p> <p>The largest body of evidence is currently available for CA‐125‐targeted antibody therapy (17 studies, 2347 participants; very low‐certainty evidence). Non‐randomised studies of CA‐125‐targeted antibody therapy suggest improved survival among humoral and/or cellular responders, with only moderate adverse events. However, four large randomised placebo‐controlled trials did not show any clinical benefit, despite induction of immune responses in approximately 60% of participants. Time to relapse with CA‐125 monoclonal antibody versus placebo, respectively, ranged from 10.3 to 18.9 months versus 10.3 to 13 months (six RCTs, 1882 participants; high‐certainty evidence). Only one RCT provided data on overall survival, reporting rates of 80% in both treatment and placebo groups (three RCTs, 1062 participants; high‐certainty evidence). Other small studies targeting many different tumour antigens have presented promising immunological results. As these strategies have not yet been tested in RCTs, no reliable inferences about clinical efficacy can be made. Given the promising immunological results and the limited side effects and toxicity reported, exploration of clinical efficacy in large well‐designed RCTs may be worthwhile. </p> </section> <section id="CD007287-sec-0007"> <h3 class="title" id="CD007287-sec-0007">Authors' conclusions</h3> <p>We conclude that despite promising immunological responses, no clinically effective antigen‐specific active immunotherapy is yet available for ovarian cancer. Results should be interpreted cautiously, as review authors found a significant dearth of relevant information for assessment of risk of bias in both RCTs and NRSs. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007287-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007287-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD007287-abs-0005">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD007287-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007287-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD007287-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007287-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007287-abs-0011">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007287-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD007287-abs-0016">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD007287-abs-0006">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007287-abs-0004" lang="en"> <h3>Antigen‐specific active immunotherapy for ovarian cancer</h3> <p><b>Background</b> <br/> Ovarian cancer is the leading cause of death from gynaecological cancers. Standard therapy consists of surgery and chemotherapy. Responses to chemotherapy are generally good; however, most women experience relapse, for which no curative treatment is available. The presence of certain immune cells in tumours is associated with longer survival. This suggests that stimulation of anti‐tumour immune responses (i.e. immunotherapy) might be a useful approach for improving outcomes among women with ovarian cancer. </p> <p><b>Review question</b><br/> This review evaluated the feasibility of antigen‐specific active immunotherapy. Antigen‐specific active immunotherapy aims to induce anti‐tumour immune responses through administration of a tumour antigen ‐ a molecule that is expressed by tumour cells and is hardly expressed by healthy cells. Reviewers collected information on clinical outcomes, immunological responses, and side effects. </p> <p><b>Main findings</b><br/> We identified 67 studies, which included 3632 women with ovarian cancer and were published between 1966 and 2017. The most frequently described strategy was administration of antibodies targeting the tumour antigen CA‐125 (2347 participants in 17 studies). Most of these studies primarily evaluated safety and immunological responses. Severe flu‐like and gastrointestinal symptoms occurred in 7% to 30% of participants. Researchers frequently detected antibodies and immune cells recognising the tumour antigen CA‐125, albeit response rates varied between studies. Despite these promising immunological responses, four large studies reported no survival advantage for participants treated with CA‐125‐directed antibody over those given placebo. </p> <p>For strategies not relying on antibody administration, similar conclusions cannot yet be drawn. Overall, study authors report that treatment was well tolerated and inflammatory side effects at the injection site were most frequently observed. Researchers observed responses of the immune system for most strategies studied, but the clinical benefit of these strategies remains to be evaluated in large trials. </p> <p><b>Certainty of the evidence and conclusions</b><br/> Because no high‐certainty evidence of clinical benefit is currently available, antibody therapy targeting CA‐125 should not be incorporated into standard treatment in its current form. </p> <p>Based on lack of uniformity in included studies, we strongly advocate universal adoption of response definitions, guidelines for adverse events reporting, and directives for trial conduct and reporting. Furthermore, results from ongoing randomised controlled trials (RCTs) are awaited, and further RCTs should be conducted. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007287-sec-0103" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007287-sec-0103"></div> <h3 class="title" id="CD007287-sec-0104">Implications for practice</h3> <section id="CD007287-sec-0104"> <p>At this point, review authors have found no evidence of effective immunotherapy for ovarian cancer. Although promising immunological responses have been observed for most strategies evaluated, they do not coincide with clinical benefits for women with ovarian cancer. Furthermore, no immunological surrogate markers currently correlate with clinical outcomes. Therefore, until evidence of true clinical effectiveness is available, immunotherapy should not be offered as an alternative to standard therapy for primary or recurrent ovarian cancer. </p> </section> <h3 class="title" id="CD007287-sec-0105">Implications for research</h3> <section id="CD007287-sec-0105"> <p>Our primary recommendation relates to the need for uniformity in trial conduct and reporting. Not until universally accepted immunological and clinical response definitions and guidelines for adverse events reporting are adopted for immunotherapeutic studies will it be possible to make any inferences about the effectiveness of immunotherapy as a treatment for ovarian cancer. Furthermore, expanding evaluation of immunogenicity to include recognition of autologous tumour is advisable. Given the usually mild side effects and the immunological responses witnessed in most studies, we believe that further investigation of antigen‐specific active immunotherapy other than cancer antigen (CA)‐125‐targeted antibody therapy for ovarian cancer in randomised controlled trials is worthwhile. In addition, research combining antigen‐targeted immunotherapy with other forms of immunotherapy to optimise response, and perhaps induce clinical response, is of interest. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007287-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007287-sec-0036"></div> <div class="table" id="CD007287-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antigen‐specific immunotherapy for ovarian carcinoma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antigen‐specific immunotherapy for ovarian carcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> ovarian carcinoma<br/> <b>Setting:</b> primary and recurrent ovarian carcinoma<br/> <b>Intervention:</b> antigen‐specific immunotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Impact</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour response<br/> assessed with: RECIST </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In total, 2 participants (0.01%) were defined as having a complete response, 9 (0.03%) had a partial response, and 50 (14%) had stable disease. Twelve participants (0.03%) showed no evidence of disease. Finally, 218 (61%) participants had progressive disease. The remaining 64 (18%) participants were not mentioned. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355<br/> (17 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour response<br/> assessed with: CA‐125 according to GCIG criteria </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In total, 8 participants (13%) were reported to have an increase in CA‐125. In 22 patients, CA‐125 was stable or decreasing (34%). The remaining 34 participants (53%) were considered not evaluable or were not mentioned. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/> (6 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐immunotherapy treatment response<br/> assessed with: survival </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Two studies suggested that antigen‐specific immunotherapy may lead to improved responses to future therapy. Two studies revealed no evidence of a difference. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (4 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival<br/> assessed with: overall survival </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None of the 3 RCTs estimating overall survival found a significant difference in overall survival. Two studies of CA‐125 monoclonal antibody vs placebo evaluated overall survival, respectively, at 57.5 vs 48.6 months (95% CI 041 to 1.25) and 80% survival for both groups. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1062<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival<br/> assessed with: progression‐free survival/time to relapse </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None of the 6 RCTs found statistically significant differences in progression‐free survival/time to relapse, including 4 RCTs evaluating CA‐125 monoclonal antibody vs placebo; time to relapse ranged from 10.3 to 18.9 months vs 10.3 to 13 months, respectively. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1882<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen‐specific immunogenicity (humoral response)<br/> assessed with: ELISA/Luminex assay </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Nine studies evaluated anti‐idiotopic (Ab2) humoral response, with responses ranging from 3% to 100%. Ten studies evaluated anti‐anti‐idiotropic (Ab3) humoral response, with responses ranging from 0% to 100%. Two studies observed no humoral response to other antigen‐specific immunotherapy, and the 9 remaining studies noted large differences in percentages of participants with measurable antigen‐specific antibodies (IgG: 8% to 96%). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1521<br/> (25 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d,g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen‐specific immunogenicity (cellular response)<br/> assessed with: e.g. IFN‐γ ELISPOT/proliferation assay/IFN‐γ secretion assay </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>A total of 39 studies showed an induced cellular immune response in at least 1 cohort and to at least 1 target antigen; range of positive response varied broadly between 18% and 100%. One study retrospectively compared cellular immune response after CA‐125 monoclonal antibody treatment vs placebo but showed no significant differences (31.8% intervention vs 26.3% control). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>966<br/> (40 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d,g,h</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Ab2: anti‐idiotopic; Ab3: anti‐anti‐idiotopic; CA: cancer antigen; CI: confidence interval; ELISA: enzyme‐linked immunosorbent assay; GCIG: Gynecologic Cancer Intergroup; IFN: interferon; RCTs: randomised controlled trials; RECIST: Response Evaluation Criteria In Solid Tumors. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Most studies were uncontrolled phase I/II trials.<br/> <sup>b</sup>A large percentage of the included participants were not mentioned or were not evaluable for the analysis.<br/> <sup>c</sup>Explicit descriptions of tumour responses per participant and the time points at which evaluations took place frequently were not available.<br/> <sup>d</sup>Disease status at start of treatment differed among studies. Therefore the likelihood of clinical and immune responses to immunotherapy, especially in uncontrolled studies, which frequently include participants with recurrent disease and previous exposure to different types of therapy, is likely to be affected.<br/> <sup>e</sup>CA‐125 is a biomarker that serves as an indication for response; however CA‐125 does not directly reflect tumour size.<br/> <sup>f</sup>Although in one study participants with a complete response had strong humoral responses, similar or stronger antibody responses were observed for participants with stable or progressive disease.<br/> <sup>g</sup>Between studies, there were broad differences in (1) response definition, (2) number of treatment cycles after which immune responses were measured, and (3) targeted antigens.<br/> <sup>h</sup>Explicit descriptions of immune responses per participant and the time points at which evaluations took place, types of evaluations, and when an evaluation was considered positive often were not available. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007287-sec-0037" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007287-sec-0037"></div> <section id="CD007287-sec-0038"> <h3 class="title" id="CD007287-sec-0038">Description of the condition</h3> <p>Ovarian cancer is the sixth most common cancer and the seventh most common cause of death from cancer among women worldwide (<a href="./references#CD007287-bbs2-0176" title="TorreLA , BrayF , SiegelRL , FerlayJ , Lortet‐TieulentJ , JemalA . Global cancer statistics, 2012. A Cancer Journal for Clinicians2015;65(2):87‐108. ">Torre 2012</a>). It is the second most common gynaecological cancer and the leading cause of death from gynaecological cancers in the Western world. As most ovarian malignancies (80% to 90%) arise from the epithelium, all statements about ovarian cancer presented in the remainder of this review apply to epithelial ovarian cancer only. Worldwide age‐standardised incidence rates range from 5 per 100,000 in less developed areas to 9.1 per 100,000 in developed areas (<a href="./references#CD007287-bbs2-0176" title="TorreLA , BrayF , SiegelRL , FerlayJ , Lortet‐TieulentJ , JemalA . Global cancer statistics, 2012. A Cancer Journal for Clinicians2015;65(2):87‐108. ">Torre 2012</a>). </p> <p>Stage of disease at presentation is the most important prognostic factor. Owing to the asymptomatic course of the disease, most participants have extensive disease at presentation (stage III to IV, according to the International Federation of Gynecology and Obstetrics (FIGO) classification (<a href="./references#CD007287-bbs2-0170" title="PratJ . FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. Journal of Gynecologic Oncology2015;26(2):87‐9. [DOI: 10.3802/jgo.2015.26.2.87] ">Prat 2015</a>)). Despite standard treatment, which consists of cytoreductive surgery and platinum‐based chemotherapy, almost all women with advanced‐stage disease at presentation will experience relapse, with median progression‐free survival of only 18 months. When residual or recurrent disease manifests itself, resistance to chemotherapy often prohibits further curative therapy, resulting in disease‐specific five‐year survival for women with advanced‐stage ovarian disease of only 10% to 20% (<a href="./references#CD007287-bbs2-0154" title="AgarwalR , LinchM , KayeSB . Novel therapeutic agents in ovarian cancer. European Journal of Surgical Oncology2006;32(8):875‐86. ">Agarwal 2006</a>; <a href="./references#CD007287-bbs2-0175" title="ThigpenJT . Chemotherapy for advanced ovarian cancer: overview of randomized trials. Seminars in Oncology2000;27(3 Suppl 7):11‐6. ">Thigpen 2000</a>). </p> </section> <section id="CD007287-sec-0039"> <h3 class="title" id="CD007287-sec-0039">Description of the intervention</h3> <p>The immune system seems to play a role in ovarian cancer. This is reflected in the observation that in more than half of women with ovarian cancer, T‐cells are present within tumour islets (<a href="./references#CD007287-bbs2-0171" title="RaspolliniMR , CastiglioneF , Rossi Degl'innocentiD , AmunniG , VillanucciA , GarbiniF , et al. Tumour‐infiltrating gamma/delta T‐lymphocytes are correlated with a brief disease‐free interval in advanced ovarian serous carcinoma. Annals of Oncology2005;16(4):590‐6. ">Raspollini 2005</a>; <a href="./references#CD007287-bbs2-0179" title="ZhangL , Conejo‐GarciaJR , KatsarosD , GimottyPA , MassobrioM , RegnaniG , et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine2003;348(3):203‐13. ">Zhang 2003</a>). Women with advanced ovarian cancer, whose tumour is infiltrated by these T‐cells, have better clinical outcomes than women without these tumour‐infiltrating T‐cells (<a href="./references#CD007287-bbs2-0160" title="DongHP , ElstrandMB , HolthA , SilinsI , BernerA , TropeCG , et al. NK‐ and B‐cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. American Journal of Clinical Pathology2006;125(3):451‐8. ">Dong 2006</a>; <a href="./references#CD007287-bbs2-0171" title="RaspolliniMR , CastiglioneF , Rossi Degl'innocentiD , AmunniG , VillanucciA , GarbiniF , et al. Tumour‐infiltrating gamma/delta T‐lymphocytes are correlated with a brief disease‐free interval in advanced ovarian serous carcinoma. Annals of Oncology2005;16(4):590‐6. ">Raspollini 2005</a>; <a href="./references#CD007287-bbs2-0179" title="ZhangL , Conejo‐GarciaJR , KatsarosD , GimottyPA , MassobrioM , RegnaniG , et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. New England Journal of Medicine2003;348(3):203‐13. ">Zhang 2003</a>). More specifically, higher numbers of cytotoxic T‐cells, which can directly recognise and kill tumour cells, and increased ratios between cytotoxic T‐cells (CD8+) and helper T‐cells (CD4+) within the tumour epithelium are associated with improved survival (<a href="./references#CD007287-bbs2-0163" title="GoodenMJM , deBockGH , LeffersN , DaemenT , NijmanHW . The prognostic influence of tumour‐infiltrating lymphocytes in cancer: a systematic review with meta‐analysis. British Journal of Cancer2011;105:93‐103. ">Gooden 2011</a>; <a href="./references#CD007287-bbs2-0173" title="SatoE , OlsonSH , AhnJ , BundyB , NishikawaH , QianF , et al. Intraepithelial CD8+ tumor‐infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favourable prognosis in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2005;102(51):18538‐43. ">Sato 2005</a>). </p> <p>Immunotherapy is one of the novel therapeutic strategies under investigation for ovarian cancer. It aims to induce or enhance active immune responses directed towards the tumour and to consolidate anti‐tumour effects of standard therapy, delaying and possibly preventing disease progression. Antigen‐specific active immunotherapy aims to activate the adaptive immune system directed towards a specific target antigen through administration of a molecularly defined antigen‐specific vaccine to the patient. </p> </section> <section id="CD007287-sec-0040"> <h3 class="title" id="CD007287-sec-0040">How the intervention might work</h3> <p>An antigen is a molecule ‐ usually a protein or a polysaccharide ‐ that can stimulate an immune response. Tumour antigens can be subdivided into different categories such as mutated self‐proteins, products of oncogenes (e.g. Her‐2/Neu), mutated tumour suppressor genes (e.g. <i>p53</i>), and aberrantly expressed self‐proteins (e.g. sperm protein 17, MAGE‐1). Numerous tumour‐associated antigens are known in ovarian cancer. To obtain a tumour‐specific immune response, immunotherapy exploits the differential expression of antigens between normal and tumour cells. A major challenge related to the safety of immunotherapy lies in the prevention of autoimmunity (i.e. induction of immune cells that preferentially recognise and kill tumour cells while avoiding destruction of normal body cells). From a theoretical point of view, other possible side effects include allergic reactions to components of the vaccine and inflammatory reactions at the site of injection. </p> </section> <section id="CD007287-sec-0041"> <h3 class="title" id="CD007287-sec-0041">Why it is important to do this review</h3> <p>Researchers are now employing several immunotherapeutic strategies by using different tumour antigens. However, this research generally has not yet evolved past phase I/II studies. To our knowledge, no systematic review of antigen‐specific active immunotherapy in ovarian cancer has been carried out so far.<br/> <br/> This review evaluates the immunogenicity and clinical efficacy of antigen‐specific active immunotherapy in ovarian cancer. A systematic review about this topic should prove useful for ascertaining the effectiveness of this treatment modality for ovarian cancer. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007287-sec-0042" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007287-sec-0042"></div> <section id="CD007287-sec-0043"> <h3 class="title" id="CD007287-sec-0043">Primary objective</h3> <p> <ul id="CD007287-list-0001"> <li> <p>To assess the clinical efficacy of antigen‐specific active immunotherapy for the treatment of ovarian cancer as evaluated by tumour response measured by Response Evaluation Criteria In Solid Tumors (RECIST) and/or cancer antigen (CA)‐125 levels, response to post‐immunotherapy treatment, and survival differences </p> <ul id="CD007287-list-0002"> <li> <p>In addition, we recorded the numbers of observed antigen‐specific humoral and cellular responses </p> </li> </ul> </li> </ul> </p> </section> <section id="CD007287-sec-0044"> <h3 class="title" id="CD007287-sec-0044">Secondary objective</h3> <p> <ul id="CD007287-list-0003"> <li> <p>To establish which combinations of immunotherapeutic strategies with tumour antigens provide the best immunological and clinical results </p> </li> </ul> </p> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007287-sec-0045" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007287-sec-0045"></div> <section id="CD007287-sec-0046"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007287-sec-0047"> <h4 class="title">Types of studies</h4> <p>We had anticipated that we would identify limited randomised controlled trials (RCTs) on this topic. Therefore, we included phase I and phase II non‐randomised studies (NRSs) and phase III RCTs. We realise that results from NRSs cannot readily be extrapolated to the general population, but given the lack of RCTs, inclusion of these studies in the review was justifiable. </p> </section> <section id="CD007287-sec-0048"> <h4 class="title">Types of participants</h4> <p>We included women with a diagnosis of epithelial ovarian cancer, irrespective of stage of disease. However, as patient populations may differ substantially between different types of studies to be included in this review, we documented what type of participant was included in each study (e.g. women with end‐stage disease, women with residual disease). </p> <p>Because we anticipated that we would find few studies that included women with ovarian cancer only, we also included immunotherapeutic studies in people with cancer that included at least two women with ovarian cancer, with the additional requirement that the results for these individual women were separately identifiable from those of the study publication or could be obtained by communication with the study author, and we extracted only data on these women for inclusion in the review. We are fully aware of the vigilance necessary when conclusions are based on studies with such small numbers, but we believe that given the anticipated lack of large RCTs, inclusion of these studies in this review is justifiable. </p> </section> <section id="CD007287-sec-0049"> <h4 class="title">Types of interventions</h4> <p>Antigen‐specific active immunotherapy is defined as therapy that aims to induce an adaptive immune response directed towards the tumour through administration of a specific well‐defined tumour antigen. We compared interventions against each other based on the above‐mentioned characteristics. </p> <p>We included all interventions that aimed to provide antigen‐specific active immunotherapy, irrespective of type of vaccine, antigen, or adjuvant used; route of vaccination; and vaccination schedule. </p> </section> <section id="CD007287-sec-0050"> <h4 class="title">Types of outcome measures</h4> <section id="CD007287-sec-0051"> <h5 class="title">Primary outcomes</h5> <section id="CD007287-sec-0052"> <h6 class="title">Clinical efficacy</h6> <p>To assess clinical efficacy, we evaluated the following.</p> <p> <ul id="CD007287-list-0004"> <li> <p>Tumour responses to immunotherapy (complete/partial response, stable/progressive disease), as measured by: </p> <ul id="CD007287-list-0005"> <li> <p>cancer antigen (CA)‐125 levels according to or transposable to Gynecologic Cancer Intergroup (GCIG) criteria (<a href="./references#CD007287-bbs2-0172" title="RustinGJ , QuinnM , ThigpenT , du BoisA , Pujade‐LauraineE , JakobsenA , et al. Re: new guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). Journal of the National Cancer Institute2004;96(6):487‐8. ">Rustin 2004</a>); or </p> </li> <li> <p>tumour response according to World Health Organization (WHO) criteria ‐ <a href="./references#CD007287-bbs2-0178" title="World Health Organization. Handbook for Reporting Results of Cancer Treatment. Geneva: World Health Organization, 1979. ">WHO 1979</a> ‐ or Response Evaluation Criteria in Solid Tumors (RECIST) criteria ‐ <a href="./references#CD007287-bbs2-0174" title="TherasseP , ArbuckSG , EisenhauerEA , WandersJ , KaplanRS , RubinsteinL , et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute2000;92(3):205‐16. ">Therasse 2000</a>. </p> </li> </ul> </li> <li> <p>We evaluated responses to post‐immunotherapy treatment, as evidence suggests that people with small cell lung cancer treated with chemotherapy after immunotherapy have improved survival as opposed to people who do not receive immunotherapy (<a href="./references#CD007287-bbs2-0155" title="AntoniaSJ , MirzaN , FrickeI , ChiapporiA , ThompsonP , WilliamsN , et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clinical Cancer Research2006;12(3):878‐87. ">Antonia 2006</a>). </p> </li> <li> <p>We assessed:</p> <ul id="CD007287-list-0006"> <li> <p>survival differences, including time to relapse or progression‐free survival, based on treatment with immunotherapy. </p> </li> </ul> </li> </ul> </p> </section> <section id="CD007287-sec-0053"> <h6 class="title">Antigen‐specific immunogenicity</h6> <p>We recorded the numbers of observed antigen‐specific humoral and cellular responses. When possible, we separately reported responses of cytotoxic (CD8+) T‐lymphocytes and/or helper (CD4+) T‐lymphocytes. </p> </section> </section> <section id="CD007287-sec-0054"> <h5 class="title">Secondary outcomes</h5> <section id="CD007287-sec-0055"> <h6 class="title">Carrier‐specific immunogenicity</h6> <p>Given that certain immunotherapeutic strategies rely on the use of carriers that may be the target of an immune response besides the intended antigen‐specific immune response, we recorded information on the induction of carrier‐specific immune responses when appropriate. </p> </section> <section id="CD007287-sec-0056"> <h6 class="title">Adverse events</h6> <p>To obtain information on the toxicity of antigen‐specific immunotherapy, we extracted data on adverse events observed and reported in the different studies. We categorised adverse events as local adverse events at the site of immunisation and systemic adverse events (all other reported adverse events). We subdivided systemic adverse events into autoimmunity, allergic reactions, and other adverse events occurring after immunisation. If sufficient information was available, we classified adverse events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (<a href="./references#CD007287-bbs2-0158" title="Common Terminology Criteria for Adverse Events v4.03. National Institutes of Health, US Department of Health and Human Services, 2009, publication # 09‐7473. ">CTCAE 2009</a>). </p> </section> </section> </section> </section> <section id="CD007287-sec-0057"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007287-sec-0058"> <h4 class="title">Electronic searches</h4> <p>For the original review (<a href="./references#CD007287-bbs2-0180" title="LeffersN , DaemenT , HelfrichW , BoezenHM , CohlenBJ , MeliefK , et al. Antigen‐specific active immunotherapy for ovarian cancer. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007287.pub2] ">Leffers 2010</a>), we searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2013, Issue 9), in the Cochrane Library (<a href="./appendices#CD007287-sec-0108">Appendix 1</a>), along with the Cochrane Gynaecological Cancer Group Specialised Register, in October 2013. We also searched MEDLINE (1966 to July 2009) and Embase (1974 to July 2009) according to the search strategies listed (<a href="./appendices#CD007287-sec-0109">Appendix 2</a>; <a href="./appendices#CD007287-sec-0110">Appendix 3</a>, respectively). </p> <p>For the first update of the review, we extended the searches to October 2013, and for this update, we extended the searches to July 2017: </p> <p> <ul id="CD007287-list-0007"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2017, Issue 6), in The Cochrane Library; </p> </li> <li> <p>MEDLINE via OVID (October 2013 to June week 4 2017);</p> </li> <li> <p>Embase via OVID (October 2013 to 2017 week 27).</p> </li> </ul> </p> </section> <section id="CD007287-sec-0059"> <h4 class="title">Searching other resources</h4> <p>We also searched the prospective trial register at <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>. </p> <p>We undertook handsearching of abstracts in the proceedings of annual meetings of the Society of Gynecologic Oncologists, the American Association for Cancer Research, and the International Society for Biological Therapy of Cancer (1996 to July 2009). The International Society for Biological Therapy of Cancer has been renamed the Society for Immunotherapy of Cancer (SITC), thus we also searched the proceedings of the annual meeting of SITC. </p> <p>We checked the bibliography of each primary reference and of recent reviews on immunotherapy for ovarian cancer for additional study publications. In addition, we wrote to specialists involved in research regarding immunotherapy for ovarian cancer to ask for information about the results of unpublished and ongoing studies. We included relevant data in this review. </p> </section> </section> <section id="CD007287-sec-0060"> <h3 class="title" id="CD007287-sec-0060">Data collection and analysis</h3> <section id="CD007287-sec-0061"> <h4 class="title">Selection of studies</h4> <p>We downloaded to Reference Manager all titles and abstracts retrieved by electronic searching. We applied no language restrictions other than those inherent to the databases surveyed. We removed duplicates, and two review authors (HWN and NL) independently examined the remaining references. We excluded studies that clearly did not meet the review inclusion criteria and obtained copies of the full text of potentially relevant references. Two review authors (HWN and NL) independently assessed the eligibility of retrieved papers. We resolved differences by discussion or by appeal to a third review author (TD), if necessary. We documented reasons for exclusion. The second update included all titles and abstracts from October 2013 until July 2017 retrieved by electronic searches of MEDLINE, Embase, and CENTRAL. Two review authors (STP and MB) selected and independently assessed studies using the same procedure that was used in the primary review and the first update. We resolved differences by discussion or by appeal to a third review author (HWN), if necessary. </p> </section> <section id="CD007287-sec-0062"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (HWN and NL) independently extracted data on characteristics of participants and interventions, study quality, and endpoints for included studies, and entered them onto a data extraction form specially developed for this review (<a href="./appendices#CD007287-sec-0111">Appendix 4</a>). Two review authors (STP and MB) followed the same procedure for the second update. </p> <p>When data on clinical efficacy and antigen‐specific immunogenicity were missing from reports, we attempted to contact study authors to obtain the missing information. A third review author (WH or TD; or HWN during the second update) checked the results. </p> </section> <section id="CD007287-sec-0063"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in RCTs using the Cochrane 'Risk of bias' tool.</p> <p>No standard tools are available to evaluate validity for non‐RCTs. For these studies, we evaluated the risk of bias using the following four domains (<a href="#CD007287-tbl-0002">Table 1</a>). </p> <div class="table" id="CD007287-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study report to assess quality of non‐randomised, non‐controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Item</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Question</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Evaluation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.</p> <p>a.</p> <p>b.</p> <p>c.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample definition and selection</b> </p> <p>Are inclusion and exclusion criteria clearly defined?</p> <p>Is the study population a representative selection of the true population?</p> <p>Are baseline characteristics adequately described?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> <p>a.</p> <p>b.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> <p>Are the interventions clearly defined (type of vaccine, antigen, adjuvant, route of vaccination, and vaccination schedule)? </p> <p>Did patients receive concurrent/concomitant treatment with immunomodulatory effects?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>a.</p> <p>b.</p> <p>c.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> <p>Are the selected outcome measures clearly specified?</p> <p>Are the outcome measures relevant?</p> <p>Are the outcome measures clearly reported?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.</p> <p>a.</p> <p>b.</p> <p>c.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical analysis</b> </p> <p>Is there an adequate rationale for the number of participants included?</p> <p>Is there an adequate description of withdrawal/exclusion of participants during the study? </p> <p>Is presentation of the results adequate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> </tbody> </table> </div> <p> <ul id="CD007287-list-0008"> <li> <p>Sample definition and selection.</p> <ul id="CD007287-list-0009"> <li> <p>Clear definition of inclusion/exclusion criteria.</p> </li> <li> <p>Representative selection.</p> </li> <li> <p>Adequate description of baseline characteristics.</p> </li> </ul> </li> <li> <p>Interventions.</p> <ul id="CD007287-list-0010"> <li> <p>Clear specification.</p> </li> <li> <p>Concurrent/concomitant treatment.</p> </li> </ul> </li> <li> <p>Outcomes.</p> <ul id="CD007287-list-0011"> <li> <p>Specifications of outcome measures.</p> </li> <li> <p>Relevance of outcome measures.</p> </li> <li> <p>Reporting of outcome measures.</p> </li> </ul> </li> <li> <p>Statistical analysis.</p> <ul id="CD007287-list-0012"> <li> <p>Adequate rationale for numbers of participants included.</p> </li> <li> <p>Adequate description of withdrawals/exclusions during the study.</p> </li> <li> <p>Adequate presentation of results.</p> </li> </ul> </li> </ul> </p> <p>We selected these domains as representative for, and applicable to, non‐randomised non‐controlled studies from a list of 12 quality domains and items deemed to be pivotal to the assessment of non‐RCTs (<a href="./references#CD007287-bbs2-0159" title="DeeksJJ , DinnesJ , D'AmicoR , SowdenAJ , SakarovitchC , SongF , et al. International Stroke Trial Collaborative Group, European Carotid Surgery Trial Collaborative Group. Evaluating non‐randomised intervention studies. Health Technology Assessment2003;7(27):1‐173. ">Deeks 2003</a>). </p> <p>Two review authors (HWN and NL) carried out the 'Risk of bias' assessment. We resolved discrepancies by discussion; if necessary, we consulted a third review author (WH or TD). For the second update, two review authors (STP and MB) carried out the 'Risk of bias' assessment. We resolved discrepancies by discussion; if necessary, we consulted a third review author (HWN). </p> </section> <section id="CD007287-sec-0064"> <h4 class="title">Data synthesis</h4> <p>This review provides a narrative analysis because the included studies are highly heterogeneous in terms of intervention and outcome measures. Furthermore, publications often presented data with insufficient details (e.g. lack of standard deviations (SDs), presentation of only some of the multiple outcomes), and it was difficult for review authors to obtain additional information from report authors. Therefore we agreed that quantitative meta‐analysis and calculation of effect size estimates would be neither meaningful nor appropriate for this review. We limited analysis to a structured summary and discussion of available studies and findings. </p> <section id="CD007287-sec-0065"> <h5 class="title">Certainty of the evidence</h5> <p>We assessed the certainty of the evidence for main outcomes using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria (<a href="./references#CD007287-bbs2-0164" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchünemannHJ , GRADE Working Group. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians?. BMJ2008;336(7651):995‐8. '>Guyatt 2008</a>), and we presented the main findings along with our judgements in a 'Summary of findings' table. </p> <p>We will present the overall certainty of the evidence for each outcome according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach (<a href="./references#CD007287-bbs2-0164" title='GuyattGH , OxmanAD , KunzR , VistGE , Falck‐YtterY , SchünemannHJ , GRADE Working Group. Rating quality of evidence and strength of recommendations: what is "quality of evidence" and why is it important to clinicians?. BMJ2008;336(7651):995‐8. '>Guyatt 2008</a>), which takes into account issues related not only to internal validity (risk of bias, inconsistency, imprecision, publication bias for quantitative studies) but also to external validity (directness of results). </p> <p>We downgraded the evidence from 'high' certainty by one level for serious (or by two for very serious) concerns for each limitation. </p> <p> <ul id="CD007287-list-0013"> <li> <p>High‐certainty: we are very confident that the true effect lies close to that of the estimate of the effect. </p> </li> <li> <p>Moderate‐certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. </p> </li> <li> <p>Low‐certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. </p> </li> <li> <p>Very low‐certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </li> </ul> </p> <p>For qualitative studies, we would upgrade for large consistent effect, dose response, and confounders that only reduced the effect size. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007287-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007287-sec-0066"></div> <section id="CD007287-sec-0067"> <h3 class="title">Description of studies</h3> <section id="CD007287-sec-0068"> <h4 class="title">Results of the search</h4> <section id="CD007287-sec-0069"> <h5 class="title">Initial version of the review</h5> <p><a href="./references#CD007287-bbs2-0180" title="LeffersN , DaemenT , HelfrichW , BoezenHM , CohlenBJ , MeliefK , et al. Antigen‐specific active immunotherapy for ovarian cancer. Cochrane Database of Systematic Reviews2010, Issue 1. [DOI: 10.1002/14651858.CD007287.pub2] ">Leffers 2010</a> </p> <p>Upon completing electronic searches of MEDLINE and Embase, we selected 56 out of 311 abstracts as potentially compliant with the selection criteria of this review and retrieved the full texts. Evaluation of the retrieved full texts resulted in the exclusion of 26 papers (see <a href="#CD007287-sec-0078">Excluded studies</a>). In addition to the 30 selected full texts, we identified another 14 abstracts by handsearching the proceedings of the periodic meetings specified in the <a href="#CD007287-sec-0045">Methods</a> section. We contacted study authors for manuscripts but obtained no full texts for these abstracts. Together, the 44 selected full texts and meeting abstracts described a total of 35 studies. A search of the prospective trial register <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> resulted in identification of an additional 26 studies. We could retrieve a full text or meeting abstract for only four of these and found that only one study complied with our inclusion criteria (<a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a>). The remaining studies were either ongoing (n = 15) or completed but not yet published (n = 6). A search of CENTRAL (2009, Issue 3) yielded no additional studies. Thus, we included a total of 36 studies in this review. Generally, we selected the most recent peer‐reviewed publication as the primary reference. </p> </section> <section id="CD007287-sec-0070"> <h5 class="title">First update of the review</h5> <p><a href="./references#CD007287-bbs2-0181" title="LeffersN , DaemenT , HelfrichW , BoezenHM , CohlenBJ , MeliefCJM , et al. Antigen‐specific active immunotherapy for ovarian cancer. Cochrane Database of Systematic Reviews2014, Issue 9. [DOI: 10.1002/14651858.CD007287.pub3] ">Leffers 2014</a> </p> <p>For the first update of this review, electronic searches of MEDLINE and Embase yielded 158 records, which resulted in an additional 23 included papers and 10 excluded papers (<a href="./references#CD007287-sec-0122" title="">Characteristics of excluded studies</a>). For five studies in the previous version of this review, a full‐text publication, update, or additional paper was now available. A search of CENTRAL (2013, Issue 3) did not yield additional studies. A search of <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> resulted in two additional published studies. Furthermore, we identified 26 relevant studies without available results (<a href="./references#CD007287-sec-0123" title="">Characteristics of ongoing studies</a>). Twelve studies are currently recruiting participants, four studies are ongoing but not recruiting, nine studies are classified as completed, and for two studies status is unknown. Overall, we included an additional 19 studies in the update of this review, resulting in a total of 55 included studies involving 3051 women (<a href="./references#CD007287-sec-0121" title="">Characteristics of included studies</a>). </p> </section> <section id="CD007287-sec-0071"> <h5 class="title">Second update of the review</h5> <p>For the second update of the review, an electronic search of CENTRAL, MEDLINE, and Embase yielded 266 records, which resulted in an additional nine included papers and nine excluded papers (<a href="./references#CD007287-sec-0122" title="">Characteristics of excluded studies</a>). For two studies identified in the previous version of this review, a full‐text publication, update, or additional paper was now available. </p> <p>A search of ongoing studies identified from the last update in <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a> revealed four additional published studies, three of which are included in this update. In addition, five studies were completed for which no results were published, four studies are still recruiting, and for one study status remains unknown. We removed four studies from the <a href="./references#CD007287-bbs1-0003" title="">Ongoing studies</a> section because the study had been terminated, or because studies did not include women with epithelial ovarian cancer. Furthermore, we identified 22 relevant new ongoing studies without available results (<a href="./references#CD007287-sec-0123" title="">Characteristics of ongoing studies</a>). </p> <p>Overall, we included an additional 12 studies in the update of this review, resulting in a total number of 67 included studies involving 3632 women (<a href="./references#CD007287-sec-0121" title="">Characteristics of included studies</a>). </p> </section> </section> <section id="CD007287-sec-0072"> <h4 class="title">Included studies</h4> <p>The 67 studies included in this updated review were all published in English (<a href="./references#CD007287-sec-0121" title="">Characteristics of included studies;</a><a href="#CD007287-tbl-0003">Table 2</a>). </p> <div class="table" id="CD007287-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disease status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease (n = 7) + recurrent disease (n = 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1 ± ErbB2 ± CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multi‐peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease after first‐ and/or second‐line chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (low dose vs high dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease after primary surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topoisomerase IIα, integrin β8 subunit precursor, ABI‐binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease after primary surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (concurrent or delayed with standard chemotherapy)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu or MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide‐pulsed dendritic cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease or recurrence after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBP, Her‐2/Neu, MAGE‐A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multi‐peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy or surgery for first recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, hTERT, PADRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide‐pulsed dendritic cells (with vs without cyclophosphamide)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fusion protein</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Synthetic long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measurable recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate (low dose vs high dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistent, recurrent, or progressive disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after first‐ or second‐line therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protein‐pulsed dendritic cells vs standard of care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First or second clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dendritic cell therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CYP1B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasmid DNA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive disease after standard chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent malignant ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody + paracentesis vs paracentesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TERT, survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mRNA‐ and peptide‐pulsed dendritic cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease after prior therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent and persistent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personalised (max 4 out of 31 vaccine candidates)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1 ± MUC1 ± CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide‐pulsed DC vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease after prior therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesothelin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant bacteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled randomised phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Five short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomsen Friedenreich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (2 vs 3 vs 6 gifts)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent or residual disease after therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after first‐ or second‐line chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I, topoisomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual disease after primary therapy or second complete remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, sTn, TF, and Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unimolecular pentavalent vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease after chemotherapy for primary or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent epithelial cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protein vaccine with Montanide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive disease after therapy</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fusion protein pulsed antigen‐presenting cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide vs peptide‐pulsed dendritic cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase Ib/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after chemotherapy for primary or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease (&lt; 2 cm) after chemotherapy for recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (intramuscular vs subcutaneous)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after chemotherapy for primary or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Lewis Y, Tn‐MUC1, Tn(c), sTN(c), TF(c)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heptavalent KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after second‐ or third‐line therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after second‐ or third‐line therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, MUC1‐TN, TF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyvalent antigen‐KLH vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM or Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifunctional antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glypican‐3 (GCP3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Advanced cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole protein vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HLA‐A24: FOXM1, MELK, HJURP, VEGFR1, VEGFR2; HLA‐A02: HIG2, VEGFR1, VEGFR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐tailored cocktail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multi‐peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease after prior chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>APC: Adenomatous polyposis coli.<br/> CA‐125: cancer antigen‐125.<br/> CDC2: Cell division control protein 2.<br/> CEA: carcinoembryonic antigen.<br/> ED: Evidence of disease.<br/> EPCAM: epithelial cell adhesion molecule.<br/> ERbB2: Human Epidermal growth factor Receptor 2.<br/> FBP: Folate binding protein.<br/> HLA: human leucocyte antigen.<br/> hTERT: telomerase reverse transcriptase.<br/> MAGE‐A1: melanoma‐associated antigen A1.<br/> MUC1: Mucin‐1.<br/> NED: No evidence of disease.<br/> NY‐ESO‐1: New York esophageal squamous cell carcinoma 1.<br/> PADRE: DR‐restricted Th helper epitope.<br/> RCT: randomised controlled trial.<br/> sTn: sialyl Tn.<br/> TERT: Telomerase Reverse Transcriptase.<br/> TF: Thompson Friedreich. </p> </div> </div> <section id="CD007287-sec-0073"> <h5 class="title">Design</h5> <p>As we expected, most studies were uncontrolled phase I or II studies (52/67). Only four studies were randomised placebo‐controlled studies (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>). Eleven studies randomly allocated participants to different regimens (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>; <a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a>; <a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>; <a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a>; <a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>; <a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a>; <a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a>; <a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>; <a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>). Five studies retrospectively studied the immunogenicity of a previously applied immunoscintigraphic agent (<a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a>; <a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a>; <a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>). </p> </section> <section id="CD007287-sec-0074"> <h5 class="title">Sample sizes</h5> <p>The median number of women with epithelial ovarian cancer treated per study was 20 (range 2 to 888). Twenty‐one studies included fewer than 10 participants. Twenty studies also included participants with other types of cancer (<a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a>; <a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a>; <a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a>; <a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a>; <a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a>; <a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a>; <a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a>; <a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a>; <a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a>; <a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a>; <a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a>; <a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a>; <a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a>; <a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a>; <a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a>; <a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a>; <a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a>; <a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a>; <a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a>; <a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>). Only 13 studies provided a sample size calculation or rationale (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>; <a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a>; <a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a>; <a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a>; <a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>; <a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a>; <a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>; <a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a>). </p> </section> <section id="CD007287-sec-0075"> <h5 class="title">Participants</h5> <p>As was expected, disease status at study entry varied largely between studies (<a href="#CD007287-tbl-0003">Table 2</a>). Participants with evidence of residual or recurrent disease after treatment were most frequently included (30/67) (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a>; <a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a>; <a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>; <a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a>; <a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a>; <a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a>; <a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a>; <a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a>; <a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>; <a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a>; <a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a>; <a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a>; <a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a>; <a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a>; <a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a>; <a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a>; <a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a>; <a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a>; <a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a>). Eight studies included participants with and without evidence of disease after prior therapy (<a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a>; <a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a>; <a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>; <a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a>; <a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a>; <a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>; <a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>; <a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>). Seventeen studies included participants with complete response to therapy for primary or recurrent disease (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a>; <a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a>; <a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>; <a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a>; <a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>; <a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a>; <a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a>; <a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a>; <a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a>; <a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a>; <a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a>; <a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>). One study administered treatment together with adjuvant chemotherapy after primary cytoreductive surgery (<a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>). The remaining 18 studies did not report disease status at study entry (<a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a>; <a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a>; <a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>; <a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a>; <a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a>; <a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a>; <a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>; <a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a>; <a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a>; <a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a>; <a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a>; <a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>; <a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a>; <a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a>; <a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a>; <a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a>; <a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a>; <a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>). </p> </section> <section id="CD007287-sec-0076"> <h5 class="title">Interventions</h5> <p>Most studies described antibody therapy (22/55), usually targeting cancer antigen (CA)‐125 (17/22 (2347 women)). Most studies included only one target antigen in the vaccine, but 15 studies simultaneously targeted multiple antigens (<a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a>; <a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a>; <a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a>; <a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a>; <a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a>; <a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a>; <a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>; <a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a>; <a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a>; <a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a>; <a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a>; <a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>; <a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a>; <a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>). Antibodies were usually administered intravenously (12/22). For other vaccine types, subcutaneous injections were most common (29/43). </p> <p>Fifteen out of 55 studies did not allow concurrent treatment with immunomodulatory drugs. In an additional 20 studies, concomitant immunomodulatory agents were not part of the studied intervention but study authors made no explicit statements in the protocol about prohibition of such drugs. For 27 studies, immunomodulatory drugs were part of the protocol (i.e. carboplatin‐paclitaxel, gemcitabine, doxorubicin and decitabine, cyclophosphamide, interleukin (IL)‐2 ± granulocyte‐macrophage colony‐stimulating factor (GM‐CSF), OK‐432, OPT‐821, PegIntron, toll‐like receptor agonist poly‐ICLC or resiquimod, or diphenhydramine) and one of these allowed interruption of immunotherapy by chemotherapy for progressive disease (<a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>). Furthermore, two retrospective studies explicitly mentioned that concurrent chemotherapy was allowed at the discretion of the treating clinician (<a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>). </p> </section> <section id="CD007287-sec-0077"> <h5 class="title">Outcomes</h5> <p>Information on immunological responses, clinical responses, survival, and adverse events was available for 63, 43, 44, and 54 studies, respectively. </p> </section> </section> <section id="CD007287-sec-0078"> <h4 class="title">Excluded studies</h4> <p>A summary of the excluded studies is given in the <a href="./references#CD007287-sec-0122" title="">Characteristics of excluded studies</a> table. Frequent reasons for exclusion were inclusion of too few participants with ovarian cancer, use of antigen non‐specific immunotherapy, and the impossibility of distinguishing results for women with ovarian cancer from results for other study participants. </p> </section> </section> <section id="CD007287-sec-0079"> <h3 class="title">Risk of bias in included studies</h3> <p>We included GRADE ratings for all primary outcomes. We rated survival as high but all other primary outcomes as very low, as is displayed in <a href="./full#CD007287-tbl-0001">summary of findings Table for the main comparison</a>. </p> <p>We evaluated risk of bias using the Cochrane 'Risk of bias' tool (<a href="./references#CD007287-bbs2-0166" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). Results of individual studies (both RCTs and NRSs) are available in the <a href="./references#CD007287-sec-0121" title="">Characteristics of included studies</a> table. The fact that for four of 16 RCTs only meeting abstracts were available hindered assessment of risk of bias. The 14 trials for which we could retrieve full texts also did not report on some of the items in the 'Risk of bias' tool. This substantial lack of information means it is highly likely that included studies are subject to biases, and it is therefore difficult to make any statements about the validity of the included RCTs (<a href="#CD007287-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007287-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. The high risk of selection bias in the majority of included studies is a reflection of the large number of uncontrolled studies included in this review. The risk of remaining biases could not be adequately judged for the included uncontrolled studies, thus explaining the large percentage of missing risk assessments." data-id="CD007287-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007287.pub4/media/CDSR/CD007287/image_n/nCD007287-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. The high risk of selection bias in the majority of included studies is a reflection of the large number of uncontrolled studies included in this review. The risk of remaining biases could not be adequately judged for the included uncontrolled studies, thus explaining the large percentage of missing risk assessments. </p> </div> </div> </div> <p>In addition to using the 'Risk of bias' tool, we evaluated non‐RCTs using the checklist provided in <a href="#CD007287-tbl-0002">Table 1</a>. An overview of these results is provided in <a href="#CD007287-tbl-0004">Table 3</a>. Important observations from this table include lack of clearly defined inclusion/exclusion criteria in 13 out of 51 studies and serious under‐reporting of baseline characteristics in 31 out of 51 studies; this combination makes it impossible to evaluate whether the study populations were representative of the true population. Although most studies carefully described the investigational interventions (47 out of 51), information on allowance or application of concomitant immunomodulatory treatment was frequently absent (24 out of 51). Albeit a clear description of outcome measures was available for 35 studies, adequate calculation of sample size based on a clearly defined primary outcome measure was available for only five studies. Furthermore, the applied checklist shows that justification for withdrawals and exclusions during the study, as well as presentation of study results, requires serious attention in the reports of these non‐randomised studies. </p> <div class="table" id="CD007287-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Assessment of quality of non‐randomised, (un)controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clear definition of inclusion/exclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Representative of true population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline characteristics adequately described</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions clearly described</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concomitant/ concurrent immunomodulatory treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measures clearly specified</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measures relevant</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measures clearly reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adequate rationale for number of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adequate description of exclusion /withdrawal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adequate presentation of results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Specified in clinical trial register, not in publication. </p> </div> </div> <p>Based on the above, the risk of bias of studies included in this systematic review cannot be neglected. Especially selection bias (selection of a treatment population not comparable to the control group or the true population), attrition bias (inadequate reporting of withdrawal and exclusions during the study, resulting in possible overestimation or underestimation of effects), and selective reporting bias are likely to affect the studies included in this review. The effects of interventions described below must therefore be interpreted with prudence. </p> <section id="CD007287-sec-0080"> <h4 class="title">Allocation</h4> <p>As can be deduced from the <a href="./references#CD007287-sec-0121" title="">Characteristics of included studies</a> table, we were unable to identify the methods of randomisation and allocation used for several randomised studies, which means that we cannot rule out a selection bias for these studies. For the remaining RCTs, selection bias does not seem likely. </p> <p>However most included studies were early‐phase non‐randomised studies including only a single study arm. Selection bias in these studies may have occurred in two ways: (1) by selective inclusion of participants with no other treatment options owing to end‐stage disease, at which point function of the immune system may also be seriously impaired, thus resulting in an underestimation of immunogenicity and possible clinical benefit of a given vaccine, or (2) via selective recruitment of fairly immunocompetent patients with no evidence of disease, resulting in a possible overestimation of immunogenicity and possible clinical benefit of a given vaccine. </p> </section> <section id="CD007287-sec-0081"> <h4 class="title">Blinding</h4> <p>Inherent to the study design, no non‐RCTs blinded participants or treating (study) physicians. All participants may have derived benefit from the additional attention awarded to them as participants in a study, and thus performance bias may have influenced the results of these studies. Furthermore, it is unclear whether for these studies, outcome assessors were aware of the clinical condition of patients; thus detection bias may have occurred in these studies. </p> <p>Only five RCTs described blinding of patients, caregivers, and/or outcome assessors; all compared antibody therapy versus placebo (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>). The other RCTs compared dosage levels (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>; <a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a>), administration route (<a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>), number of gifts of a given drug (<a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>), timing of the intervention in relation to standard chemotherapy (<a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>), addition of an immunomodulatory drug (<a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a>), or immunotherapeutic intervention compared with standard of care (<a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a>; <a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>; <a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a>). Given these study designs, we believe that for most of these studies, risk of performance bias is low. Information on blinding of outcome assessors is frequently missing, and risk of detection bias cannot be reliably judged. </p> </section> <section id="CD007287-sec-0082"> <h4 class="title">Incomplete outcome data</h4> <p>We deemed that only one RCT had high risk of attrition bias based on differences in withdrawals between groups (<a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a>). Risk of attrition bias was unclear for nine other RCTs (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a>; <a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>; <a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a>; <a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>; <a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a>; <a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>; <a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>), and risk was low for the remaining RCTs (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>; <a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>). </p> </section> <section id="CD007287-sec-0083"> <h4 class="title">Selective reporting</h4> <p>None of the included studies had a publicly available registered study protocol. It is therefore unclear whether studies selectively reported outcomes. </p> </section> <section id="CD007287-sec-0084"> <h4 class="title">Other potential sources of bias</h4> <p>Given the elapsed time since publication of the meeting abstract, a publication bias is likely to exist for two out of three RCTs for which only a meeting abstract was available (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>). </p> </section> </section> <section id="CD007287-sec-0085"> <h3 class="title" id="CD007287-sec-0085">Effects of interventions</h3> <p>See: <a href="./full#CD007287-tbl-0001"><b>Summary of findings for the main comparison</b> Antigen‐specific immunotherapy for ovarian carcinoma</a> </p> <section id="CD007287-sec-0086"> <h4 class="title">Primary outcomes</h4> <section id="CD007287-sec-0087"> <h5 class="title">Clinical efficacy</h5> <section id="CD007287-sec-0088"> <h6 class="title">Tumour responses</h6> <p>Forty‐three studies evaluated clinical responses to therapy (<a href="#CD007287-tbl-0005">Table 4</a>). No RCTs evaluated tumour response (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>). In reports on these studies, criteria for evaluation and/or explicit descriptions of tumour responses per patient as well as the time point at which the evaluation took place were frequently not available. For studies that did mention evaluation of tumour responses, response outcomes were based on CA‐125 levels combined with tumour imaging (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a>; <a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a>; <a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>; <a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a>; <a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>; <a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a>; <a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a>; <a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a>; <a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a>; <a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>; <a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a>; <a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>; <a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a>; <a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a>), CA‐125 alone (<a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a>; <a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>), or imaging alone (<a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a>; <a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>; <a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a>; <a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>; <a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a>; <a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a>). Eighteen studies explicitly mentioned evaluation of imaging according to the internationally accepted WHO or RECIST criteria (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a>; <a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a>; <a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>; <a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a>; <a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a>; <a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a>; <a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a>; <a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a>; <a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>; <a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a>; <a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a>; <a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a>; <a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a>; <a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>; <a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a>), and only six studies evaluated CA‐125 levels according to GCIG criteria or described CA‐125 levels in such a way that evaluation according to these criteria was possible for at least some participants (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a>; <a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a>; <a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a>; <a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a>). It is striking that eight studies stated that study authors evaluated tumour responses but did not provide these results in their publications (<a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a>; <a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>; <a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a>; <a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a>; <a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>; <a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>; <a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>; <a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>). Only seven studies reported complete or partial tumour responses in a small fraction of patients with evidence of disease at study entry (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a>; <a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a>; <a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>; <a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>; <a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a>). These results must be interpreted with caution, as two of these studies did not define criteria for response evaluation (<a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>). </p> <div class="table" id="CD007287-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Evaluation of clinical responses to immunotherapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>CA‐125</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Tumour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall conclusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Response definition</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Results</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Definition for tumour response</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Results</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1 (baseline status; disease free): 1× PD and 6× NED</p> <p>Cohort 2 (baseline status; recurrent disease): 3× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6× NED</p> <p>4× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines (evaluable patients: cohort 1: 7; cohort 2: 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 7× ↑, Cohort 2: 3× ↑</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× SD, 21× PD</p> <p>Cohort 2: 1× PR, 5× SD, 16× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× SD, 21× PD</p> <p>Cohort 2: 1× PR, 5× SD, 16× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>                  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>complete clinical remission 15×/18×</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 1× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a>       </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× NED, 8× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× PD, 7× NED</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>            </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3 (n = 6): 4× PD, 2× PR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3 (n = 6): 2× PR, 3× PD, 1× SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3: 2× PR, 3× PD, 1× SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>                 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>decrease &gt; 15% (↓); &lt; 15% change (=) stable; <br/> &gt; 15% increase (↑) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4× ↓, 1× =, 6× ↑</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× SD, 10× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>                 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18× SD, 10× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× ↓, 3× =, 16× ^?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14× SD, 7× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14× SD, 7× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>               </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6× ↓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× NED, 2× CR, 1× PR, 1× SD, 9× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 3× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 3× SD, 21× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 3× SD, 21× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST 3 months after first vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PR, 14× SD, 32× PD</p> <p>Disease controle rate: 29%</p> <p>Objective response rate: 3.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR: 3.6%, SD: 25%, PD: 57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 18× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5× PD, 2× NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4× SD, 4× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a>              </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× SD, 7× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× SD, 11× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a>            </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21× PD, 1× SD, 1× lost to follow‐up, 3× unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>               </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 17× unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× PD, 5× SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PD: 10%, SD:50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× SD, 3× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× SD, 4× PD, 1× withdrawal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 2× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 2× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× NED, 11× PD</p> <p>Cohort 2: 2× NED, 5× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× NED, 11× PD</p> <p>Cohort 2: 2× NED, 5× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>         </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>          </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12× SD, 21× PD, 9× withdrawal (6× PD)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 1× NED, 3× PD</p> <p>Cohort 2: 3× NED, 10× PD</p> <p>Cohort 3: 2× NED, 9× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 1× NED, 3× PD</p> <p>Cohort 2: 3× NED, 10× PD</p> <p>Cohort 3: 2× NED, 9× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× PD, 1× PR or SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months: PR: 2/32, PD: 28/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PR, 28× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 2× PR, 10× SD, 9× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 2× PR, 10× SD, 9× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>           </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4× PD, 1× SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× ↓, 1× =, 1× ↑, 2× unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× NED, 1× SD, 2× PD, 1× unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× PD, 2× SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7× ↓/=, 3× ↑</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 8× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>    </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>C1: cohort 1.<br/> C2: cohort 2.<br/> C3: cohort 3.<br/> CA‐125: cancer antigen‐125.<br/> CR: complete response.<br/> GCIG: Gynecologic Cancer Intergroup.<br/> NED: no evidence of disease.<br/> PD: progressive disease.<br/> PR: partial response.<br/> RECIST: Response Evaluation Criteria In Solid Tumors.<br/> SD: stable disease.<br/> WHO: World Health Organization. </p> </div> </div> </section> <section id="CD007287-sec-0089"> <h6 class="title">Post‐immunotherapy treatment response</h6> <p>Although studies generally report a period of follow‐up to obtain information on survival, most studies provide no report on subsequent treatment with and response to secondary chemotherapy. Nine studies mention that participants were treated with chemotherapy after immunotherapy (<a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a>; <a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>; <a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>; <a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a>; <a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a>), but only four non‐comparative phase I/II studies report response to secondary chemotherapy in relation to immunological responses to immunotherapy (<a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a>; <a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>). </p> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> provided a preliminary report on clinical responses of 28 out of 42 participants treated with chemotherapy for clinically relevant progression during or after antibody therapy in conjunction with the induction of human‐anti‐mouse and anti‐anti‐idiotype antibodies. Although both types of participants with a complete response had strong humoral responses, researchers observed similar or stronger antibody responses for participants with stable or progressive disease. In another study, shortly after monotherapy with a monoclonal antibody, 13 out of 20 participants received chemotherapy combined with the monoclonal antibody. Researchers in this study observed clinical responses to chemo‐immunotherapy only in patients with cellular responses to CA‐125 and/or autologous tumour (<a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>). A study of synthetic long peptides targeting <i>p53</i> showed no improvement in survival or tumour responses to secondary chemotherapy (<a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>). Finally, the authors of a study investigating plasmid DNA vaccination targeting CYP1B1 suggest that treatment has led to improved responses to third‐line therapy but included no control group, nor do we find this observation convincing when only patients with ovarian cancer are considered (<a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a>). </p> </section> <section id="CD007287-sec-0090"> <h6 class="title">Survival and time to relapse</h6> <p>Definitions of survival used in the different studies varied greatly (<a href="#CD007287-tbl-0006">Table 5</a> and <a href="#CD007287-tbl-0007">Table 6</a>). Furthermore, reliable statements about survival (dis)advantages can be made only on the basis of RCT findings. Only six studies were designed to primarily evaluate survival; however, investigators found no statistically significant differences in time to relapse and/or overall survival between patients treated with a monoclonal antibody and those given placebo (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>). Another study compared antigen‐specific immunotherapy versus a non‐specific immunotherapy and noted no significant differences in progression‐free survival (<a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>). Another study compared MUC1 dendritic cell therapy versus standard of care and reported no significant differences in progression‐free survival and overall survival. However, when patients were divided into two subgroups (first and second clinical remission), a significant difference in overall survival and progression‐free survival was evident among those with a second clinical remission. Researchers included a small number of participants in the trial and median overall survival of the treated group has not yet been reached; therefore these results must be interpreted with caution (<a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>). Many non‐RCTs also evaluated survival, frequently by comparing survival of patients with robust immunological responses versus that of patients with no or weak immunological responses to treatment (<a href="#CD007287-tbl-0006">Table 5</a> and <a href="#CD007287-tbl-0007">Table 6</a>). These results should be interpreted with great caution, as shorter survival among non‐responders could merely be a reflection of the general condition of these patients and might reflect well‐known clinical and pathological prognostic parameters. Patient numbers in the non‐comparative groups were often too low to permit a reliable conclusion. </p> <div class="table" id="CD007287-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Definitions and results of survival and/or relapse analysis in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: low dose 70 days (95% CI 63 to 91), high dose 68 days (95% CI 58 to 77) </p> <p>median overall survival: low dose 137 days (95% CI 99 to 218), high dose 185 days (95% CI 134 to 472) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to relapse: placebo 11.3, robust HAMA 16.4, robust Ab2 18.9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>all patients: time to relapse: oregovomab 13.3 vs placebo 10.3 months (P = 0.71) (HR 0.881, 95% CI 0.578 to 1.349) </p> <p>successful front‐line therapy patients: time to relapse: oregovomab 24 vs placebo 10.8 months (P = 0.71) (HR 0.543, 95% CI 0.287 to 1.025) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to relapse (randomisation to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to relapse: oregovomab 10.3 months (95% CI 9.7 to 13.0 months) vs placebo 12.9 months (95% CI 10.1 to 17.4 months) (P = .29) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: simultaneous administration 17.9 months vs delayed administration 16.1 months  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression/survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression: median 8.4 weeks (range 2 to 61 weeks); survival 37 weeks (range 11 to 110) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression/survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression: median 11 weeks (T‐cell responders vs non‐responders; P &lt; 0.0001; HR 0.150, 95% CI 0.006 to 0.168); survival: median 70.4 weeks (T‐cell responders vs non‐responders; P &lt; 0.002; HR 0.157, 95% CI 0.009 to 0.347) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>puncture‐free survival (first dose to therapeutic puncture or death)/overall survival (first dose to death) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median puncture‐free survival: paclitaxel + catumaxomab 52 days (95% CI 38 to 62) vs catumaxomab 11 days (95% CI 9 to 20) </p> <p>Median overall survival: paclitaxel + catumaxomab 110 days (95% CI 70 to 164) vs catumaxomab 81 days (95% CI 68 to 134) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)/overall survival (diagnosis to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival: median 16.8 months (95% CI 10.3 to 22.6) (Ab3 responders vs non‐responders 18.2 vs 13.1, P = 0.0896; HAMA responders vs non‐responders 22.6 months vs 7.6 months, P = 0.0016); overall survival: median 34.4 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival and 3‐year survival: Ab3 responders vs non‐responders 22.9 vs 13.5 months, P = 0.0089, 38% vs 8%; T‐cell responders vs non‐responders (n = 16) &gt; 84 vs 13.2 months, P = 0.0202, 75% vs 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival: 19.4 months, Ab3 responders vs non‐responders: 23.4 vs 4.9 months, P &lt; 0.0001 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression: 4 months (95% CI 3 to 5 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recurrence‐free survival (randomisation to recurrence)/overall survival (randomisation to death) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median recurrence‐free survival: abagovomab 403 days (95% CI 323 to 414) vs placebo 402 days (95% CI 323 to 487) </p> <p>2‐year overall survival rate: abagovomab 80% (SE 1.71) vs placebo 80% (SE 2.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival (diagnosis to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: robust Ab3 responders vs non‐robust responders 49 vs 38 months, P = 0.0029; Ab2 robust vs non‐robust responders 30.0 vs 44.0 months, P = 0.0475 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not described separately for ovarian cancer patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival: 22.0 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival: robust Ab2 vs non‐robust Ab2 responders: NS</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Ab2: anti‐idiotype antibody.<br/> Ab3: anti‐anti‐idiotype antibody.<br/> CI: confidence interval.<br/> HAMA: human‐anti‐mouse antibody.<br/> HR: hazard ratio.<br/> SE: standard error. </p> </div> </div> <div class="table" id="CD007287-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Definitions and results of survival and/or relapse analysis in other antigen‐specific immunotherapy studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recurrence rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recurrence rate: n = 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (study day 0 to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression &gt; 8 months (range 4 to &gt; 9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival (first vaccination to relapse)/overall survival (first vaccination to death/last follow‐up) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐year progression‐free survival: arm 1 vs arm 2, 40% vs 80% (P = 0.17)</p> <p>3‐year overall survival: arm 1 vs arm 2, 80% vs 100% (P = 1.00) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (last chemo to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression 13.0 months (95% CI 11.2 to not reached)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: time from start of therapy until progression in weeks</p> <p>overall survival: time from start of therapy until death in weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progression‐free survival cohort 3: 8 to 36 (median 13)</p> <p>Overall survival cohort 3: 12 to 48 (median 37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free interval; survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free interval: 4 months (95% CI 1.9 to 7.6)</p> <p>median survival: 13.3. months (95% CI 1.5 to 30.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: 12.2 months (range 1.3 to 38.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival; overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival vaccine vs standard of care 365 days vs 321 days</p> <p>overall survival: not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival</p> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: 13 months (Cvac) vs 9 months (standard of care)</p> <p>overall survival: median not reached at 43 months in both study arms.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival; overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: 9, 18, 19+ months; OS: 6, 19+, 21 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (first vaccination to relapse)/overall survival (first vaccination to death) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time overall (n = 42): 19.1 months</p> <p>median survival time platinum‐sensitive (n = 17): 39.3 months</p> <p>median survival time platinum‐resistant (n = 25): 16.2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time from first vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time 14.5 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>disease‐specific survival (diagnosis to death of ovarian cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median disease‐specific survival participants vs historical controls: 44.0 months vs 47.4 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (trial entry to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival: 12.7 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: 2 months (range 1 to 36)</p> <p>median overall survival: 15.5 months (range 1.5 to &gt; 57.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: not reached (range 289 to 1115+ days)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: time from the end of adjuvant chemotherapy until disease progression </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not adequately described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (first vaccination to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 19.0 months (95% CI 9.0 to not reached)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: 21 months (95% CI 16 to 29 months)</p> <p>median overall survival: 48 months (95% CI not estimable)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 14.0 (range 12.1 to 18.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival (date on study to date of progression)</p> <p>overall survival (date on study to date of death or last follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: 4.2 vs 8.7 months</p> <p>median overall survival: 40.8 vs 29.6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (trial entry to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 6 months (range 2 to 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (first vaccination to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 4.2 months (95% CI 2.7 to 8.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no differences between cohorts (numbers not reported)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: time from randomisation to first clinical, biochemical, or radiological evidence of progression </p> <p>overall survival: time from study untill death.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: 5.9 months vaccine + OPT‐821 vs 6.5 months OPT‐821 only</p> <p>overall survival: 46.5 months vaccine + OPT‐821 vs 46.2 months OPT‐821 only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time of progression: not reported</p> <p>overall survival after 12 months of all patients: 20.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: HLA‐A24 5 months (range 30 to 623 days), HLA‐A02 9 months (range 54 to 921 days) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </div> </section> <section id="CD007287-sec-0091"> <h6 class="title">Antigen‐specific immunogenicity</h6> <section id="CD007287-sec-0092"> <p><b>Humoral responses</b></p> <p>Monoclonal antibodies may induce anti‐idiotype antibodies (Ab2), directed primarily against the administered monoclonal antibody, as well as anti‐anti‐idiotype antibodies (Ab3), directed towards the target antigen. Anti‐idiotype and anti‐anti‐idiotype antibodies were evaluated in 10 out of 22 studies and 9 out of 22 studies, respectively (<a href="#CD007287-tbl-0008">Table 7</a> and <a href="#CD007287-tbl-0009">Table 8</a>). Response percentages varied greatly (Ab2: 3% to 100%, Ab3: 0% to 100%). </p> <div class="table" id="CD007287-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Definitions and results of anti‐idiotypic (Ab2) humoral responses in antigen‐specific monoclonal antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Robust if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% robust</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% vs 74%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐50‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13% vs 31% vs 67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 250 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0 μ/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 10 μ/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32%</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD007287-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Definitions and results of anti‐anti‐idiotypic (Ab3) humoral responses in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Robust if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% robust</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes; reported in <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐50‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.015 μg/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L vs S: 100% vs 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 μ/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 μ/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo: stable</p> <p>abagovomab: increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> </div> <p>Twenty‐one studies of other vaccine types evaluated the induction of antigen‐specific antibodies as shown by enzyme‐linked immunosorbent assay (ELISA) or luminex assay; however only 11 of these studies clearly defined when an antibody titre or concentration was considered positive (<a href="#CD007287-tbl-0010">Table 9</a>) (<a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>; <a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a>; <a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a>; <a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>; <a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a>; <a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a>; <a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a>; <a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>; <a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a>; <a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a>). In addition, the study combining an NY‐ESO‐1 vaccine with chemotherapy and an anti‐methylation agent tested humoral response with ELISA to 22 recombinant proteins that were not included in the vaccine and showed de novo serum reactivity to at least one of those proteins in all analysed participants (n = 3), suggesting that combination regimens may lead to a broadened profile of anti‐tumour immune response in vivo (<a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a>). Results show large differences in percentages of patients with measurable antigen‐specific antibodies (IgG: 0% to 96%). Possible explanations for these broad ranges include differences in (1) response definition, (2) number of treatment cycles after which humoral responses were measured, and (3) targeted antigens. </p> <div class="table" id="CD007287-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Definitions and results of humoral response evaluation in other antigen‐specific immunotherapy studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assay</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1 ± ErbB1 ± CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>topoisomerase IIα, integrin β8 subunit precursor, ABI‐binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBP, Her‐2/Neu, MAGE‐A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, hTERT, PADRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2× pretreatment and &gt; mean + 2 SD of 10 normal sera</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CYP1B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TERT, survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high response: &gt; 0.6</p> <p>intermediate response: 0.2 to 0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% high responses, 40% intermediate responses</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>personalised (max 4 out of 31 vacinne candidates)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luminex assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 out of 4 vaccine‐specific IgG titers is 2‐fold higher than pre‐vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 vaccinations: 16/42</p> <p>12 vaccinations: 29/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1 ± MUC1 ± CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mesothelin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pre‐imm: 40%, post‐imm: 45%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomsen Friedenreich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% IgA, 90% IgM, 90% IgG, 0% IgE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1, CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I, toposiomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Tn, TF, sTN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IgM titer &gt; 1:80 or at least 4‐fold increase from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IgM: GM2 25%, Globo‐H 8%, Tn 58%, TF 67%, sTn 92%</p> <p>IgG: GM2 17%, Globo‐H 58%, Tn 83%, TF 25%, sTN 67%</p> <p>20/24 responded to at least 3 antigens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>reciprocal titer &gt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 patients remained seropositive</p> <p>5/6 became seropositive</p> <p>no differences between cohorts.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lewis Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Lewis Y, Tn‐MUC1, Tn(c), sTN(c), TF(c)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>negative to ≥ 1:40 or 8‐fold increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% ≥ 3 antigens; 22% GM2, 33% Globo‐H, 11% Lewis Y, 100% Tn‐MUC1, 44% Tn(c), 44% sTN(c), 78% TF(c) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cohort 1: 25%, C2: 46%, C3: 91%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, MUC1‐TN, TF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:40 or 2‐fold increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IgG: GLOBO‐H 7%, GM2 8%, MUC1‐TN 32%, MUC1 45%, TF 13%</p> <p>IgM: GLOBO‐H 21%, GM2 26%, MUC1‐TN 40%, MUC1 49%, TF 22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1:20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% IgM, 80% IgG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GPC3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>optical density cutoff value 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HLA‐A24: FOXM1, MELK, HJURP, VEGFR1, VEGFR2</p> <p>HLA‐A02: HIG2, VEGFR1, VEGFR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patient‐tailored cocktail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p>SD: standard deviation.</p> </div> </div> </section> <section id="CD007287-sec-0093"> <p><b>Cellular responses</b></p> <p>Thirteen out of 20 monoclonal antibody studies investigated induction of T‐cells against the target antigen (<a href="#CD007287-tbl-0011">Table 10</a>). Investigators evaluated the presence of antigen‐specific T‐cells using commonly applied tests, such as interferon‐gamma (IFN‐γ) ELISPOT (<a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>; <a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>; <a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>), proliferation assay (<a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a>; <a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a>; <a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a>), cytokine profiling (<a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a>; <a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a>), IFN‐γ secretion assay (<a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a>), and IFN‐γ intracellular staining assay (<a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a>). One study used the leucocyte migration inhibition assay, which nowadays is rarely used (<a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>). As described above for humoral responses, response definitions were frequently lacking or inadequate. Nevertheless, results showed cellular immunity against CA‐125 for 21% to 80% of participants. One study retrospectively compared cellular immune response after CA‐125 monoclonal antibody treatment versus placebo but noted no significant differences (31.8% intervention vs 26.3% control) (<a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a>). Antibody treatment targeting the membrane folate receptor did not however induce cellular responses (<a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a>). Only two studies reported recognition of autologous tumour cells by induced T‐cells, describing positive responses in five out of eight and one out of two patients, respectively (<a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a>). </p> <div class="table" id="CD007287-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Definitions and results of cellular responses in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assay</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>permutation test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44% vs 21% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>flow cytometry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patients with a CA‐125‐CTL count above 0.410 × 10^6 (=90th percentile level of CA‐125‐specific CTL count in the placebo arm) for at least 1 of the time points throughout the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.8% (treatment arm) vs 26.3% (placebo arm)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>permutation test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4 CA‐125: 75%; n = 3 oregovomab 67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>permutation test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 18 CA‐125: 39%; n = 8 oregovomab 50%; n = 8 autologous tumour cells 63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐5‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4: 50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay/ cytokine ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay: Wilcoxon signed rank test; cytokine ELISA: unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 17 CA‐125 53%; Th1 cytokines 41%, Th2 cytokines 94%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cytokine flow cytometry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2‐fold increase in IFN‐γ‐expressing T‐cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L vs S: n = 12 vs 17, CD4: 58% vs 29%; CD8 75% vs 18%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>spots experimental wells ‐ control wells &gt; 20 and experimental wells/control wells &gt; 1.5× </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 5: 80%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ secretion assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM n = 1 (100%)</p> <p>Her‐2/Neu n = 1 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>leucocyte migration inhibition assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CTL: cytotoxic T‐cell.</p> </div> </div> <p>A total of 35 out of 44 studies evaluated antigen‐specific cellular immune responses with the use of other vaccine types (<a href="#CD007287-tbl-0012">Table 11</a>). The most frequently used assay was the IFN‐γ ELISPOT assay, which sometimes was used to separately analyse CD4+ and/or CD8+ cells. Again, response definitions for positive and/or vaccine‐induced responses were frequently absent or unclear (15 out of 44). Six of eight studies targeting NY‐ESO‐1 induced antigen‐specific T‐cells, with percentages of patients with NY‐ESO‐1‐specific CD8+ ranging from 33% to 92% (<a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a>; <a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>; <a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a>; <a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>; <a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a>; <a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a>; <a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a>), and one study did not report the results for ovarian cancer participants separately (<a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a>). Another study showed a positive NY‐ESO‐1‐specific CD8+ T‐cell induction by IFN‐γ catch assay (1% to 5% positive CD8+ T‐cells) (<a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a>). After treatment with vaccines targeting <i>p53</i> , investigators observed <i>p53</i>‐specific T‐cells in 64% to 100% of patients, irrespective of the type of vaccine (<a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a>; <a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a>; <a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a>). One study compared <i>p53</i> ‐specific T‐cell responses between treatment with a <i>p53</i>‐targeting vaccine plus chemotherapy and PegIntron versus chemotherapy and PegIntron versus chemotherapy alone. Immune response rates were 100%, 22%, and 0%, respectively (<a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a>), indicating that applying chemotherapy and PegIntron at the same time as antigen‐targeted immunotherapy may induce a stronger immune response. Studies targeting multiple antigens demonstrated antigen‐specific cellular immunity with varying immunogenicity of the different antigens targeted (<a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a>; <a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a>; <a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a>; <a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a>; <a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a>; <a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>; <a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a>; <a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>; <a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a>; <a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a>; <a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a>; <a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a>; <a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>). Finally, a study testing dendritic cell‐based immunotherapy showed no induction of IFN‐γ‐specific CD4+ and CD8+ cells by flow cytometry, although tetramer staining of WT1‐specific cytotoxic T‐lymphocytes did show an increase in 12 out of 17 patients (70.6%) (<a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a>). </p> <div class="table" id="CD007287-tbl-0012"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Definitions and results of cellular responses in other antigen‐specific immunotherapy studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assay</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1 ± ErbB1 ± CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ ELISPOT</p> <p>delayed hypersensitvity test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: 2‐fold increase in IFN‐γ production</p> <p>Delayed hypersensitvity test: unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: 6/7 + 0/3</p> <p>Delayed hypersensitvity test: 3/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>topoisomerase IIα, integrin β8 subunit precursor, ABI‐binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pentamer staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2× increase in pentamer‐positive CD8‐cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% against at least 1 peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>tetramer staining</p> <p>intracellular cytokine staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>combined results cohort 2 + 3: 92% on ≥ 2 assays</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intracellular IFN‐γ staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 1: Her‐2/Neu 100%; n = 2: MUC1 50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBP, Her‐2/Neu, MAGE‐A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 9: FBP 40%, Her‐2/Neu 83%, MAGE‐A1 83%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, hTERT, PADRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>tetramer staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>hTERT: cohort 1: 100%, cohort 2: 100%</p> <p>Her‐2/Neu: cohort 1: 60%, cohort 2: 0%</p> <p>PADRE: cohort 1: 60%, cohort 2: 60%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>intracellular cytokine staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3: gemcitabine, PegIntron, and p53 SLP vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3‐fold change compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cohort 3: 6/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT/Tetramer staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots &gt; 30 and &gt; 3× spots irrelevant control &gt; 0.1% tetramer‐positive CD8‐cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both assays n = 9: 67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intracellular cytokine staining (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inadequately reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CYP1B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>spots minus negative control &gt; 20/10⁶ PBMC and &gt; 2× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 5: 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)/IFN‐γ ELISA (CD4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: ≥ 2‐fold increase in IFN‐γ‐secreting cells</p> <p>IFN‐γ ELISA: unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 3: 100% CEA</p> <p>n = 3: 33% CEA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TERT, survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intracellular cytokine staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall &gt; 90%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>personalised (max 4 out of 31 vaccine candidates)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐fold higher values post‐vaccination than pre‐vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 vaccinations: 18/42</p> <p>12 vaccinations: 19/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1 ± MUC1 ± CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flow cytometry (CD4/CD8/NK)</p> <p>Tetramer staining (WT‐1 CTLs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>flow cytometry: no chances in CD4+, CD8+, and NK cell frequency</p> <p>tetramer staining: 12/17 increased</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mesothelin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots &gt; 2× baseline and ≥ 1 per 10⁵ PBMC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 1 evaluable, mesothelin‐specific CD8 cells present</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>proliferation assay</p> <p>intracellular cytokine staining (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots ≥ 10/10⁵ PBMC and ≥ 3× pre‐immunisation</p> <p>cpm &gt; 1000/min, SI ≥ 3, and ≥ 2× pre‐immunisation</p> <p>≥ 3 pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 18: 100%</p> <p>n = 17: 82%</p> <p>n = 5: CD8 0%, CD4 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT/HLA‐multimer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8): spot number &gt; 10 and 2‐fold higher than background and 2‐fold higher than standard deviation of all combined negative values </p> <p>HLA‐multimer staining: detection of &gt; 50 cells in the multimer gate, minimum percentage of 0.03% CD8+ cells </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ex vivo ELISPOT: n = 0/7</p> <p>in vivo ELISPOT: n = 1/2</p> <p>ex vivo multimer: n = 2/5</p> <p>in vivo multimer: n = 3/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tetramer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomsen Friedenreich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1, CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2× pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2: 0%; MUC1‐specific CD8 cells 50%, CEA‐specific CD8 cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I, toposiomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 40 spots/10⁶ PBMC over pre‐vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 8: 63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4: 75%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Tn, TF, sTN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± 3 SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 18; CD4: 83%, CD8: 33%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> <p>intracellular cytokine staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD4: 91%</p> <p>CD8: 45%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> <p>tetramer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: spot numbers in the presence of target cells exceeded cutoff value (&gt; 50 spots/50,000 cells) + at least 3 times more spots than unpulsed target cells </p> <p>tetramer: &gt; 0.1% tetramer‐positive cells are CD8+ T‐cells and at least 3 times more than the percentage obtained with control tetramer. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD8: 5/11 (45%), of which 3 de novo inductions</p> <p>CD4: 7/10 (70%), of which 2 de novo responses</p> <p>tetramer staining: 2× NY‐ESO‐1 CD8 cell expansion</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay</p> <p>ELISPOT assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported separately for ovarian cancer patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>tetramer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2× pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cohort 1: 64%, cohort 2: 83%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lewis Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Lewis Y, Tn‐MUC1, Tn(c), sTN(c), TF(c)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 spots/5 × 10⁴ cells and &gt; 3× unstimulated cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD4: 100% in cohort 1, 2, and 3</p> <p>CD8: cohort 1: 0%, cohort 2: 62%, cohort 3: 92%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, MUC1‐TN, TF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; upper limit of normal (SI 2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4: 50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GPC3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 15/24: 62.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ catch assay (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD4: n = 2; &gt; 5%</p> <p>CD8: n = 2; 1% to 5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HLA‐A24: FOXM1, MELK, HJURP, VEGFR1, VEGFR2</p> <p>HLA‐A02: HIG2, VEGFR1, VEGFR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inadequately reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patient‐tailored cocktail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2 after 6 vacc 100%; n = 1 after 12 vacc 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>proliferation assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots ≥ 10/10⁵ PBMC and ≥ 3× pre‐immunisation</p> <p>cpm &gt; 1000/min, SI ≥ 3, and ≥ 2× pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% after 2 vacc, 87.5% after 4 vacc</p> <p>80% after 2 vacc, 62.5% after 4 vacc</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>as measured after at least three immunisations. <br/> C1: cohort 1.<br/> SD: standard deviation.<br/> SI: stimulation index. </p> </div> </div> </section> </section> </section> </section> <section id="CD007287-sec-0094"> <h4 class="title">Secondary outcomes  </h4> <section id="CD007287-sec-0095"> <h5 class="title">Carrier‐specific immunogenicity</h5> <p>Most studies using a monoclonal antibody (18/22) used a murine antibody, two studies used a trifunctional rat‐mouse hybrid (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a>), and one study used a chimeric antibody construct (<a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a>). Next to antigen‐specific immunity, 16 studies assessed the induction of human‐anti‐mouse antibodies (HAMAs) using HAMA‐specific ELISA assays (<a href="#CD007287-tbl-0013">Table 12</a>). HAMAs were present in 4% to 97% of participants immunised (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>; <a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>; <a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a>; <a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>; <a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>; <a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a>). It seems that this large variation between studies cannot be attributed to differences in dosage but is best ascribed to different definitions of a HAMA response (i.e. some studies report only robust responses, whereas others report all responses above a certain threshold). Furthermore, the point in time at which HAMA titres were measured is of importance, as responses increase in frequency and strength with repeated administration of the antibody (<a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a>; <a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>; <a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>). </p> <div class="table" id="CD007287-tbl-0013"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Definitions and results of human‐anti‐mouse antibody (HAMA) evaluation in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Robust if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% robust</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 61%, C2: 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIM vs OWD: 100% vs 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIM vs OWD: 88% vs 74%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes; reported in <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐50‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4% vs 36% vs 39%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg       </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 15 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L vs S: 94% vs 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inadequately reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (n = 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>n.r.: not reported.</p> </div> </div> <p>Although eight studies investigated synthetic carbohydrate antigens conjugated to the keyhole limpet haemocyanin (KLH) carrier protein (<a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>; <a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a>; <a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a>; <a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a>; <a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a>; <a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a>; <a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a>; <a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a>), only one study reported on KLH‐specific immunity (<a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a>). In this study, proliferative responses to stimulation with KLH and the KLH‐antigen complex were substantially stronger than responses to the synthetic carbohydrate itself in all women with ovarian cancer tested, similar to what has previously been reported for viral vectors. </p> <p>Five studies reported use of recombinant viruses or bacteria as vectors (<a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a>; <a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a>; <a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a>; <a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a>; <a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a>). Three of these studies reported that they investigated anti‐vector immune responses. One study used a recombinant pox‐virus induced anti‐vector immunity for all participants with ovarian cancer (<a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a>). Another study used a recombinant measles virus and did not show any differences in anti‐measles‐antibody titres, although inclusion criteria required that included participants must be immune to measles virus (<a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a>). In the third study, use of live‐attenuated listeria did result in virus‐specific T‐cells in some cancer patients; however, too few patients with ovarian cancer were tested to permit any conclusions regarding this specific disease entity (<a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a>). </p> </section> <section id="CD007287-sec-0096"> <h5 class="title">Adverse events</h5> <p>For this review, we defined adverse events as any adverse changes in health or side effects that occurred in a clinical study participant receiving treatment, irrespective of whether the event could be attributed to the treatment received. </p> <p>Although 56 studies mentioned adverse events; sufficiently detailed information on adverse events that occurred during the study was available for 43 out of 67 studies. Thirty‐four studies explicitly mentioned local adverse events, all of which involved local administration of the vaccine (i.e. intradermal, intramuscular, or subcutaneous injection). When local adverse events were further specified, these were best summarised as pain at the injection site and local inflammatory responses (erythema, induration, pruritis). Researchers observed ulceration and/or abscesses at the injection site in nine of 89 participants with varying types of cancer participating in four studies (<a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a>; <a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a>; <a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>; <a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a>). One study described a patient with a grade III infection presenting with lower‐limb lymphoedema at the injection site, which was attributed to the vaccine. This patient underwent a pelvic lymphadenectomy during the primary debulking surgery, suggesting in this case that women who have undergone pelvic lymphadenectomy might be less suitable for vaccination of the lower limbs (<a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>). </p> <p>Systemic adverse events occurred in 42 studies, and four studies explicitly reported that systemic adverse events did not occur. Two studies explicitly reported autoimmunity. In one study, a patient with strong immunological responses to the vaccine developed symptomatic hypothyroidism necessitating replacement therapy (<a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>). Study authors described minor induction of anti‐nuclear antibodies (grade I according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 (<a href="./references#CD007287-bbs2-0177" title="TrottiA , ColevasA , SetserV , RuschD , JaquesV , BudachC , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology2003;13(3):176‐81A. ">Trotti 2003</a>)) for two patients receiving a multi‐peptide vaccine (<a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a>). Allergic reactions occurred in a total of 14 participants (<a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>; <a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>; <a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a>; <a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a>). Allergic reactions (e.g. hypersensitivity, allergic exanthema, urticaria) were mild and were easily managed. Continuation of study treatment did not result in renewed allergic reactions (<a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>; <a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a>). Treatment with chemotherapy, an anti‐methylation agent, and an NY‐ESO‐1‐targeting vaccine resulted in clinically manageable adverse events (<a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a>). </p> <p>Other reported systemic adverse events, irrespective of whether attributable to the investigated drug, included haematological changes (e.g. anaemia, leucopenia), flu‐like symptoms (including fatigue, myalgia, arthralgia, headache, fever, and chills), and gastrointestinal events (e.g. nausea, vomiting, diarrhoea, abdominal pain), most of which were classified as grade I or II events. Thirty‐three studies reported serious (CTCAE grade III or IV) adverse events that varied from recurrent or progressive disease to local ulceration at the injection site, and from abdominal pain, neutropenia, and fever to elevated liver enzymes. One study compared standard of care versus MUC1 dendritic cell therapy. Respectively, 8% versus 27% of participants suffered an adverse event grade III or IV (<a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a>). Another study combining vaccination with chemotherapy reported 10 high‐grade adverse events, nine of which were attributed to the chemotherapy (<a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a>). In addition, one study comparing chemotherapy alone versus chemotherapy and PegIntron versus chemotherapy, PegIntron, and <i>p53</i> vaccination reported grade III or IV adverse events in 50% of participants, with no significant differences between treatment groups (<a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a>). A study combining chemotherapy, an anti‐methylation agent, and an NY‐ESO‐1‐targeting vaccine described three serious adverse events, which study authors did not attribute to any of the investigated drugs (<a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a>). Twenty studies reported no serious adverse events. Ten studies did not mention lack or presence of serious adverse events (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a>; <a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a>; <a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a>; <a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a>; <a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a>; <a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a>; <a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a>; <a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a>; <a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007287-sec-0097" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007287-sec-0097"></div> <section id="CD007287-sec-0098"> <h3 class="title" id="CD007287-sec-0098">Summary of main results</h3> <p>The aim of this review was to evaluate the clinical and immunological efficacy of antigen‐specific active immunotherapy in ovarian cancer, whilst also obtaining an impression of the safety and tolerability of this treatment modality. The antigen‐specific active immunotherapy described in this review can largely be divided into two strategies: (1) administration of antibodies targeting a specific tumour antigen and (2) administration of, or parts of, a specific tumour antigen itself. As expected, most studies were non‐randomised controlled trials (NRSs). </p> <p>Data suggest that almost all strategies are capable of inducing an immunological response to some extent. Furthermore, only two studies evaluated recognition of autologous tumour cells in vitro, and no studies evaluated immune responses at the tumour site. Although obtaining autologous tumour material may be burdensome, such assays would be extremely valuable, as they comprise true interactions between induced immunity and tumour cells and as such could provide important information on how immunotherapeutic strategies can continue to be improved to reach clinical effectiveness. Even though comparison between studies is difficult, it seems that most antigen‐specific therapies, independent of the target, are able to induce at least a minimal immune response. </p> <p>Clinical responses to immunotherapy (i.e. tumour responses, responses to post‐immunotherapy treatment, and survival benefits) were observed only incidentally, and their occurrence cannot be used to draw a reliable conclusion. The indication for immunotherapeutic treatment in the adjuvant setting is supported by the observation of enhanced antigen‐specific responses to immunotherapy when combined with chemotherapeutic agents currently or previously used in the primary treatment of ovarian cancer (i.e. docetaxel or cyclophosphamide) (<a href="./references#CD007287-bbs2-0162" title="GarnettCT , SchlomJ , HodgeJW . Combination of docetaxel and recombinant vaccine enhances T‐cell responses and antitumor activity: effects of docetaxel on immune enhancement. Clinical Cancer Research2008;14(11):3536‐44. ">Garnett 2008</a>; <a href="./references#CD007287-bbs2-0167" title="LaheruD , LutzE , BurkeJ , BiedrzyckiB , SoltS , OnnersB . Allogeneic granulocyte macrophage colony‐stimulating factor‐secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation. Clinical Cancer Research2008;14(5):1455–63. ">Laheru 2008</a>). However, four large randomised controlled trials (RCTs) using a monoclonal cancer antigen (CA)‐125 antibody in the adjuvant setting after successful primary therapy did not demonstrate any differences in time to relapse and/or overall survival between treatment and placebo arms (<a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a>; <a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a>; <a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a>; <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a>), which indicates that despite immunogenicity, CA‐125‐targeted monoclonal antibody therapy is clinically ineffective. For studies of other vaccine types, no such conclusions can be made at this time, as large RCTs and more studies in the adjuvant rather than recurrent setting have yet to be performed to examine the different strategies. </p> <p>Eighty per cent of studies reported adverse events in sufficient detail for interpretation. Study authors made a distinction between local and systemic events and further subdivided the latter into autoimmunity, allergy, and other adverse events. We did not evaluate whether adverse events could be or were considered attributable to the treatment studied, although for local adverse events, this is indisputably the case. Studies using intradermal, subcutaneous, or intramuscular application have frequently reported inflammatory reactions and pain at the injection site, with ulceration at the most severe side of the spectrum. Severe or life‐threatening systemic adverse events occurred in approximately 50% of studies. Thirty per cent of studies explicitly described the lack of severe adverse events. For monoclonal antibody studies, researchers could identify no pattern suggestive of an underlying treatment‐associated process and often considered events to be associated with ovarian cancer progression. </p> <p>In summary, this review describes 67 immunotherapy studies including 3632 women with ovarian cancer. It seems that although all strategies described are capable of inducing immunological responses, be it humoral or cellular, clinical effectiveness thus far has not been convincingly demonstrated. The largest body of evidence is available for CA‐125‐directed antibody therapy, which has been studied in 2347 people participating in 17 studies. As only one study reported complete or partial clinical responses and four large RCTs did not demonstrate any clinical benefit of antibody treatment, we believe it is unlikely that the clinical effectiveness of CA‐125‐directed antibody therapy for ovarian cancer will ever be obtained. It is possible that inducing an immunological response alone is not enough to derive clinical benefit owing to immune suppressive characteristics of the tumour. To overcome this suppression, combining antigen‐specific immunotherapy with other forms of immunotherapy (e.g. checkpoint inhibitors, chemotherapy, poly ADP ribose polymerase (PARP) inhibitors, anti‐methylation agents) might be necessary to achieve clinical response. However, in view of the immunological responses and the usually mild side effects reported, we believe that further investigation of other antigen‐specific active immunotherapy strategies in ovarian cancer is worthwhile. </p> </section> <section id="CD007287-sec-0099"> <h3 class="title" id="CD007287-sec-0099">Overall completeness and applicability of evidence</h3> <p>The most striking observations of this review unfortunately do not concern the aim of the review but address lack of uniformity in the conduct and reporting of early‐phase immunotherapy studies. </p> <p>According to the GRADE rating, only certainty for the primary outcome survival is assessed as 'high', whereas that for all other outcomes is assessed as 'very low' (<a href="./full#CD007287-tbl-0001">summary of findings Table for the main comparison</a>). Of note, most of the RCTs that were analysed for survival were investigating a CA‐125 monoclonal antibody. Their results may not be applicable in a similar way for other strategies using antigen‐specific immune therapy for ovarian carcinoma. </p> <p>Reliability of the results for clinical response to immunotherapy was questionable because clear response definitions were lacking, and because concomitant immunotherapy or administration of additional treatment after immunotherapy often was not described. Furthermore, for studies that used a monoclonal antibody targeting CA‐125, use of CA‐125 as a marker for clinical response is questionable. An additional important comment regarding the likelihood of clinical response to immunotherapy, especially in uncontrolled studies, which frequently include patients with recurrent disease, is the fact that this likelihood may be affected by disease status at the start of treatment (<a href="./references#CD007287-bbs2-0168" title="LeffersN , DaemenCAHH , van derZeeAGJ , NijmanHW . Multimodality treatment warranted for ovarian cancer: immunotherapy, a prerequisite to improve prognosis for this vicious disease. Immunotherapy2009;1(2):163‐5. ">Leffers 2009</a>). </p> <p>In addition, antigen‐specific humoral and/or cellular immunogenicity of different interventions showed great variation for both monoclonal antibody studies and studies examining other strategies. This variation may be attributed at least in part to variation in the immunological response definitions used by different study authors. Therefore it is not possible to reliably compare studies and infer which intervention and/or immunisation strategy is most promising for the induction of strong anti‐tumour immunity. </p> <p>A disturbing observation regarding adverse events is the lack of uniformity in adverse event reporting. Reporting of safety and tolerability of new treatment strategies should have high priority in all studies of investigational drugs, especially in uncontrolled phase I and II studies. To promote uniformity in adverse event evaluation and reporting, as well as comparability of adverse events between studies, in addition to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) (<a href="./references#CD007287-bbs2-0177" title="TrottiA , ColevasA , SetserV , RuschD , JaquesV , BudachC , et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in Radiation Oncology2003;13(3):176‐81A. ">Trotti 2003</a>), the Brighton Collaboration has committed itself to developing standardised, widely disseminated, and globally accepted case definitions for an exhaustive number of adverse events following immunisation, as well as guidelines for data collection, analysis, and presentation (<a href="./references#CD007287-bbs2-0156" title="Brighton Collaboration. www.brightoncollaboration.org. ">Brighton Collaboration 2009</a>). These case definitions and guidelines are freely available, and we strongly recommend that, when applicable, they be used for all immunotherapeutic studies. </p> <p>This review emphasises an aspect of immunotherapeutic studies that warrants serious attention in the immunotherapeutic scientific community, that is, lack of consensus on (1) what assays should be used to establish immunogenicity of an intervention (<a href="./references#CD007287-bbs2-0157" title="BrittenCM , GouttefangeasC , WeltersMJ , PawelecG , KochS , OttensmeierC , et al. The CIMT‐monitoring panel: a two‐step approach to harmonize the enumeration of antigen‐specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunology, Immunotherapy2008;57(3):289‐302. ">Britten 2008</a>), (2) what cutoffs should be used to define true immunological responses, and (3) what response definitions should be used to determine clinical efficacy. Given these large inconsistencies, it is evident that elucidation of which type of immunological response is necessary for and/or is a surrogate marker of clinical activity of an immunotherapeutic intervention is burdensome. </p> </section> <section id="CD007287-sec-0100"> <h3 class="title" id="CD007287-sec-0100">Quality of the evidence</h3> <p>We assessed the included studies for risks of bias, using the Cochrane 'Risk of bias' tool. Risk of bias items, especially selection, attrition, and selective reporting bias, are likely to affect the studies included in this review. </p> <p>It is interesting to note that for 10 studies described in this review, review authors collected study information only from a meeting abstract that was several years old. The lack of full‐text manuscripts, even after contact was made with abstract authors, strongly suggests the existence of a publication bias. To avoid the disappearance of negative studies, registration of trials in a prospective trial register is widely recommended and is supported by the International Committee of Medical Journal Editors (ICMJE). However, at first, in 2005, registration was requested only for RCTs. Since July 1, 2008, all trials prospectively assigning human participants to one or more health‐related interventions for evaluation of their effects on health outcomes are required to be registered in a clinical trial register approved by the World Health Organization (WHO). From the ongoing studies section, it is apparent that despite registration in a prospective trial register, studies may suffer from publication bias, as several relatively small studies that began more than five years ago have not yet been published to date nor closed according to the trial register. In addition to registration in trial registers, the uniform requirements for manuscripts submitted to biomedical journals drafted by the ICMJE encourage uniformity in reporting of clinical trials by stating ethical principles for the conduct and reporting of research and by providing recommendations related to specific elements of editing and writing. As is obvious from this review, the scientific community might benefit substantially if early‐phase uncontrolled clinical trials would also strive for uniformity in trial conduct and reporting. </p> </section> <section id="CD007287-sec-0101"> <h3 class="title" id="CD007287-sec-0101">Potential biases in the review process</h3> <p>We minimised potential biases in the review process by searching the literature from a variety of sources with no restrictions on date of publication. At least two review authors independently extracted and assessed data. </p> <p>To minimise the chances of error and bias, review authors adhered to Cochrane guidelines for selection of studies, extraction of data, and assessment of the certainty of evidence and potential risks of different types of biases in all included studies. </p> </section> <section id="CD007287-sec-0102"> <h3 class="title" id="CD007287-sec-0102">Agreements and disagreements with other studies or reviews</h3> <p>Our findings are in broad agreement with those presented by most systematic reviews on antigen‐specific active immunotherapy for ovarian cancer (<a href="./references#CD007287-bbs2-0161" title="DrerupJM , LiuY , PadronAS , MurthyK , HurezV , ZhangB , CurielTJ . Immunotherapy for ovarian cancer. Current Treatment Options in Oncology2015;16(1):317. ">Drerup 2015</a>; <a href="./references#CD007287-bbs2-0165" title="HardwickN , FrankelPH , CristeaM . New approaches for immune directed treatment for ovarian cancer. Current Treatment Options in Oncology2016;17(3):14. ">Hardwick 2016</a>; <a href="./references#CD007287-bbs2-0169" title="OdunsiK . Immunotherapy in ovarian cancer. Annals of Oncology2017;28(8):viii1–viii7. ">Odunsi 2017</a>). However, the focus of current publications leans more towards immunotherapy in general (e.g. whole tumour lysate‐targeting immunotherapy, immune checkpoint blockade, cytokine induction, adoptive cell transfer) and not towards antigen‐specific immunotherapy alone. The general consensus is that antigen‐specific immunotherapy is sufficient for eliciting an immune response, but clinical response to monotherapy is only modest (<a href="./references#CD007287-bbs2-0161" title="DrerupJM , LiuY , PadronAS , MurthyK , HurezV , ZhangB , CurielTJ . Immunotherapy for ovarian cancer. Current Treatment Options in Oncology2015;16(1):317. ">Drerup 2015</a>; <a href="./references#CD007287-bbs2-0169" title="OdunsiK . Immunotherapy in ovarian cancer. Annals of Oncology2017;28(8):viii1–viii7. ">Odunsi 2017</a>). Combining antigen‐specific immunotherapy with other types of immunotherapy, especially immune checkpoint blockade, is a promising approach to be examined by future researchers (<a href="./references#CD007287-bbs2-0165" title="HardwickN , FrankelPH , CristeaM . New approaches for immune directed treatment for ovarian cancer. Current Treatment Options in Oncology2016;17(3):14. ">Hardwick 2016</a>; <a href="./references#CD007287-bbs2-0169" title="OdunsiK . Immunotherapy in ovarian cancer. Annals of Oncology2017;28(8):viii1–viii7. ">Odunsi 2017</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007287-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/media/CDSR/CD007287/urn:x-wiley:14651858:media:CD007287:CD007287-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/media/CDSR/CD007287/image_t/tCD007287-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. The high risk of selection bias in the majority of included studies is a reflection of the large number of uncontrolled studies included in this review. The risk of remaining biases could not be adequately judged for the included uncontrolled studies, thus explaining the large percentage of missing risk assessments." data-id="CD007287-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007287.pub4/media/CDSR/CD007287/image_n/nCD007287-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. The high risk of selection bias in the majority of included studies is a reflection of the large number of uncontrolled studies included in this review. The risk of remaining biases could not be adequately judged for the included uncontrolled studies, thus explaining the large percentage of missing risk assessments. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/media/CDSR/CD007287/image_n/nCD007287-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007287-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antigen‐specific immunotherapy for ovarian carcinoma</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Antigen‐specific immunotherapy for ovarian carcinoma</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Patient or population:</b> ovarian carcinoma<br/> <b>Setting:</b> primary and recurrent ovarian carcinoma<br/> <b>Intervention:</b> antigen‐specific immunotherapy </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Impact</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="1" valign="top"> <p><b>Certainty of the evidence<br/> (GRADE)</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour response<br/> assessed with: RECIST </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In total, 2 participants (0.01%) were defined as having a complete response, 9 (0.03%) had a partial response, and 50 (14%) had stable disease. Twelve participants (0.03%) showed no evidence of disease. Finally, 218 (61%) participants had progressive disease. The remaining 64 (18%) participants were not mentioned. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>355<br/> (17 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,d</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tumour response<br/> assessed with: CA‐125 according to GCIG criteria </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>In total, 8 participants (13%) were reported to have an increase in CA‐125. In 22 patients, CA‐125 was stable or decreasing (34%). The remaining 34 participants (53%) were considered not evaluable or were not mentioned. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64<br/> (6 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,b,c,d,e</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Post‐immunotherapy treatment response<br/> assessed with: survival </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Two studies suggested that antigen‐specific immunotherapy may lead to improved responses to future therapy. Two studies revealed no evidence of a difference. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>88<br/> (4 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,f</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival<br/> assessed with: overall survival </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None of the 3 RCTs estimating overall survival found a significant difference in overall survival. Two studies of CA‐125 monoclonal antibody vs placebo evaluated overall survival, respectively, at 57.5 vs 48.6 months (95% CI 041 to 1.25) and 80% survival for both groups. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1062<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Survival<br/> assessed with: progression‐free survival/time to relapse </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>None of the 6 RCTs found statistically significant differences in progression‐free survival/time to relapse, including 4 RCTs evaluating CA‐125 monoclonal antibody vs placebo; time to relapse ranged from 10.3 to 18.9 months vs 10.3 to 13 months, respectively. </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1882<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> High </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen‐specific immunogenicity (humoral response)<br/> assessed with: ELISA/Luminex assay </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Nine studies evaluated anti‐idiotopic (Ab2) humoral response, with responses ranging from 3% to 100%. Ten studies evaluated anti‐anti‐idiotropic (Ab3) humoral response, with responses ranging from 0% to 100%. Two studies observed no humoral response to other antigen‐specific immunotherapy, and the 9 remaining studies noted large differences in percentages of participants with measurable antigen‐specific antibodies (IgG: 8% to 96%). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>1521<br/> (25 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d,g</sup> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Antigen‐specific immunogenicity (cellular response)<br/> assessed with: e.g. IFN‐γ ELISPOT/proliferation assay/IFN‐γ secretion assay </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>A total of 39 studies showed an induced cellular immune response in at least 1 cohort and to at least 1 target antigen; range of positive response varied broadly between 18% and 100%. One study retrospectively compared cellular immune response after CA‐125 monoclonal antibody treatment vs placebo but showed no significant differences (31.8% intervention vs 26.3% control). </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>966<br/> (40 observational studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> Very low<sup>a,d,g,h</sup> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Ab2: anti‐idiotopic; Ab3: anti‐anti‐idiotopic; CA: cancer antigen; CI: confidence interval; ELISA: enzyme‐linked immunosorbent assay; GCIG: Gynecologic Cancer Intergroup; IFN: interferon; RCTs: randomised controlled trials; RECIST: Response Evaluation Criteria In Solid Tumors. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence.</b> <br/> <b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/> <b>Moderate certainty:</b> we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/> <b>Low certainty:</b> our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.<br/> <b>Very low certainty:</b> we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Most studies were uncontrolled phase I/II trials.<br/> <sup>b</sup>A large percentage of the included participants were not mentioned or were not evaluable for the analysis.<br/> <sup>c</sup>Explicit descriptions of tumour responses per participant and the time points at which evaluations took place frequently were not available.<br/> <sup>d</sup>Disease status at start of treatment differed among studies. Therefore the likelihood of clinical and immune responses to immunotherapy, especially in uncontrolled studies, which frequently include participants with recurrent disease and previous exposure to different types of therapy, is likely to be affected.<br/> <sup>e</sup>CA‐125 is a biomarker that serves as an indication for response; however CA‐125 does not directly reflect tumour size.<br/> <sup>f</sup>Although in one study participants with a complete response had strong humoral responses, similar or stronger antibody responses were observed for participants with stable or progressive disease.<br/> <sup>g</sup>Between studies, there were broad differences in (1) response definition, (2) number of treatment cycles after which immune responses were measured, and (3) targeted antigens.<br/> <sup>h</sup>Explicit descriptions of immune responses per participant and the time points at which evaluations took place, types of evaluations, and when an evaluation was considered positive often were not available. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Antigen‐specific immunotherapy for ovarian carcinoma</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study report to assess quality of non‐randomised, non‐controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Item</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Question</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Evaluation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1.</p> <p>a.</p> <p>b.</p> <p>c.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Sample definition and selection</b> </p> <p>Are inclusion and exclusion criteria clearly defined?</p> <p>Is the study population a representative selection of the true population?</p> <p>Are baseline characteristics adequately described?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> <p>a.</p> <p>b.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions</b> </p> <p>Are the interventions clearly defined (type of vaccine, antigen, adjuvant, route of vaccination, and vaccination schedule)? </p> <p>Did patients receive concurrent/concomitant treatment with immunomodulatory effects?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> <p>a.</p> <p>b.</p> <p>c.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcomes</b> </p> <p>Are the selected outcome measures clearly specified?</p> <p>Are the outcome measures relevant?</p> <p>Are the outcome measures clearly reported?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4.</p> <p>a.</p> <p>b.</p> <p>c.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Statistical analysis</b> </p> <p>Is there an adequate rationale for the number of participants included?</p> <p>Is there an adequate description of withdrawal/exclusion of participants during the study? </p> <p>Is presentation of the results adequate?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Yes No ?</p> <p>Yes No ?</p> <p>Yes No ?</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study report to assess quality of non‐randomised, non‐controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of included studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Design</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Disease status</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Type of intervention</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease (n = 7) + recurrent disease (n = 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1 ± ErbB2 ± CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multi‐peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease after first‐ and/or second‐line chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (low dose vs high dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>317</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease after primary surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Topoisomerase IIα, integrin β8 subunit precursor, ABI‐binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease after primary surgery</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (concurrent or delayed with standard chemotherapy)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu or MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide‐pulsed dendritic cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary treatment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease or recurrence after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBP, Her‐2/Neu, MAGE‐A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multi‐peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy or surgery for first recurrence</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, hTERT, PADRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide‐pulsed dendritic cells (with vs without cyclophosphamide)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fusion protein</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary surgery and chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>P53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Synthetic long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Measurable recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate (low dose vs high dose)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Persistent, recurrent, or progressive disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after first‐ or second‐line therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protein‐pulsed dendritic cells vs standard of care</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Randomised phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>First or second clinical remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Dendritic cell therapy</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CYP1B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Plasmid DNA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive disease after standard chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent malignant ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody + paracentesis vs paracentesis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TERT, survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mRNA‐ and peptide‐pulsed dendritic cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease after prior therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent and persistent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Personalised (max 4 out of 31 vaccine candidates)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1 ± MUC1 ± CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide‐pulsed DC vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Evidence of disease after prior therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Mesothelin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant bacteria</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled randomised phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Five short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomsen Friedenreich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (2 vs 3 vs 6 gifts)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent or residual disease after therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after first‐ or second‐line chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I, topoisomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual disease after primary therapy or second complete remission</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, sTn, TF, and Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unimolecular pentavalent vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease after chemotherapy for primary or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recombinant virus</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent epithelial cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Protein vaccine with Montanide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive disease after therapy</p> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Fusion protein pulsed antigen‐presenting cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptide vs peptide‐pulsed dendritic cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase Ib/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after chemotherapy for primary or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease (&lt; 2 cm) after chemotherapy for recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody (intramuscular vs subcutaneous)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after chemotherapy for primary or recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Lewis Y, Tn‐MUC1, Tn(c), sTN(c), TF(c)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Heptavalent KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after second‐ or third‐line therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after primary therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody vs placebo</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No evidence of disease after second‐ or third‐line therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, MUC1‐TN, TF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Polyvalent antigen‐KLH vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>KLH conjugate</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progressive disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM or Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Trifunctional antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Glypican‐3 (GCP3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Advanced cancer</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Whole protein vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HLA‐A24: FOXM1, MELK, HJURP, VEGFR1, VEGFR2; HLA‐A02: HIG2, VEGFR1, VEGFR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Short peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>(No) evidence of disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient‐tailored cocktail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Multi‐peptide vaccine</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase I/II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Residual or recurrent disease after prior chemotherapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uncontrolled phase II</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent disease</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Long peptides</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Retrospective uncontrolled</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Antibody</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>APC: Adenomatous polyposis coli.<br/> CA‐125: cancer antigen‐125.<br/> CDC2: Cell division control protein 2.<br/> CEA: carcinoembryonic antigen.<br/> ED: Evidence of disease.<br/> EPCAM: epithelial cell adhesion molecule.<br/> ERbB2: Human Epidermal growth factor Receptor 2.<br/> FBP: Folate binding protein.<br/> HLA: human leucocyte antigen.<br/> hTERT: telomerase reverse transcriptase.<br/> MAGE‐A1: melanoma‐associated antigen A1.<br/> MUC1: Mucin‐1.<br/> NED: No evidence of disease.<br/> NY‐ESO‐1: New York esophageal squamous cell carcinoma 1.<br/> PADRE: DR‐restricted Th helper epitope.<br/> RCT: randomised controlled trial.<br/> sTn: sialyl Tn.<br/> TERT: Telomerase Reverse Transcriptase.<br/> TF: Thompson Friedreich. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of included studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Assessment of quality of non‐randomised, (un)controlled studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Clear definition of inclusion/exclusion criteria</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Representative of true population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Baseline characteristics adequately described</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Interventions clearly described</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Concomitant/ concurrent immunomodulatory treatment</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measures clearly specified</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measures relevant</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Outcome measures clearly reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adequate rationale for number of patients</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adequate description of exclusion /withdrawal</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Adequate presentation of results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="13"> <div class="table-footnote"> <p><sup>a</sup>Specified in clinical trial register, not in publication. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Assessment of quality of non‐randomised, (un)controlled studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Evaluation of clinical responses to immunotherapy</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Method</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>CA‐125</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="1" valign=""> <p><b>Tumour</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Overall conclusion</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Response definition</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Results</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Definition for tumour response</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><i>Results</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1 (baseline status; disease free): 1× PD and 6× NED</p> <p>Cohort 2 (baseline status; recurrent disease): 3× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6× NED</p> <p>4× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines (evaluable patients: cohort 1: 7; cohort 2: 3) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 7× ↑, Cohort 2: 3× ↑</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× SD, 21× PD</p> <p>Cohort 2: 1× PR, 5× SD, 16× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× SD, 21× PD</p> <p>Cohort 2: 1× PR, 5× SD, 16× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a>                  </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18/22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>complete clinical remission 15×/18×</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 1× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a>       </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× NED, 8× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× PD, 7× NED</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a>            </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3 (n = 6): 4× PD, 2× PR</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3 (n = 6): 2× PR, 3× PD, 1× SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3: 2× PR, 3× PD, 1× SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a>                 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>decrease &gt; 15% (↓); &lt; 15% change (=) stable; <br/> &gt; 15% increase (↑) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4× ↓, 1× =, 6× ↑</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× SD, 10× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a>                 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18× SD, 10× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× ↓, 3× =, 16× ^?</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14× SD, 7× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14× SD, 7× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a>               </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6× ↓</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× NED, 2× CR, 1× PR, 1× SD, 9× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 3× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 3× SD, 21× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 3× SD, 21× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST 3 months after first vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PR, 14× SD, 32× PD</p> <p>Disease controle rate: 29%</p> <p>Objective response rate: 3.6%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PR: 3.6%, SD: 25%, PD: 57%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 18× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5× PD, 2× NE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4× SD, 4× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a>              </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× SD, 7× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× SD, 11× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a>            </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21× PD, 1× SD, 1× lost to follow‐up, 3× unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a>               </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 17× unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× PD, 5× SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PD: 10%, SD:50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× SD, 3× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× SD, 4× PD, 1× withdrawal</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 2× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 2× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× NED, 11× PD</p> <p>Cohort 2: 2× NED, 5× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 2× NED, 11× PD</p> <p>Cohort 2: 2× NED, 5× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a>         </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a>          </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12× SD, 21× PD, 9× withdrawal (6× PD)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 1× NED, 3× PD</p> <p>Cohort 2: 3× NED, 10× PD</p> <p>Cohort 3: 2× NED, 9× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 1: 1× NED, 3× PD</p> <p>Cohort 2: 3× NED, 10× PD</p> <p>Cohort 3: 2× NED, 9× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× PD, 1× PR or SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12 months: PR: 2/32, PD: 28/32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PR, 28× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tumour</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 2× PR, 10× SD, 9× PD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× CR, 2× PR, 10× SD, 9× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a>           </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WHO</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4× PD, 1× SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× ↓, 1× =, 1× ↑, 2× unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1× NED, 1× SD, 2× PD, 1× unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3× PD, 2× SD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Gynaecologic Cancer Intergroup Guidelines</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7× ↓/=, 3× ↑</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>RECIST</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2× SD, 8× PD</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a>    </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>C1: cohort 1.<br/> C2: cohort 2.<br/> C3: cohort 3.<br/> CA‐125: cancer antigen‐125.<br/> CR: complete response.<br/> GCIG: Gynecologic Cancer Intergroup.<br/> NED: no evidence of disease.<br/> PD: progressive disease.<br/> PR: partial response.<br/> RECIST: Response Evaluation Criteria In Solid Tumors.<br/> SD: stable disease.<br/> WHO: World Health Organization. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Evaluation of clinical responses to immunotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Definitions and results of survival and/or relapse analysis in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: low dose 70 days (95% CI 63 to 91), high dose 68 days (95% CI 58 to 77) </p> <p>median overall survival: low dose 137 days (95% CI 99 to 218), high dose 185 days (95% CI 134 to 472) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to relapse: placebo 11.3, robust HAMA 16.4, robust Ab2 18.9 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>all patients: time to relapse: oregovomab 13.3 vs placebo 10.3 months (P = 0.71) (HR 0.881, 95% CI 0.578 to 1.349) </p> <p>successful front‐line therapy patients: time to relapse: oregovomab 24 vs placebo 10.8 months (P = 0.71) (HR 0.543, 95% CI 0.287 to 1.025) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to relapse (randomisation to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to relapse: oregovomab 10.3 months (95% CI 9.7 to 13.0 months) vs placebo 12.9 months (95% CI 10.1 to 17.4 months) (P = .29) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: simultaneous administration 17.9 months vs delayed administration 16.1 months  </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression/survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression: median 8.4 weeks (range 2 to 61 weeks); survival 37 weeks (range 11 to 110) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression/survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression: median 11 weeks (T‐cell responders vs non‐responders; P &lt; 0.0001; HR 0.150, 95% CI 0.006 to 0.168); survival: median 70.4 weeks (T‐cell responders vs non‐responders; P &lt; 0.002; HR 0.157, 95% CI 0.009 to 0.347) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>puncture‐free survival (first dose to therapeutic puncture or death)/overall survival (first dose to death) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Median puncture‐free survival: paclitaxel + catumaxomab 52 days (95% CI 38 to 62) vs catumaxomab 11 days (95% CI 9 to 20) </p> <p>Median overall survival: paclitaxel + catumaxomab 110 days (95% CI 70 to 164) vs catumaxomab 81 days (95% CI 68 to 134) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)/overall survival (diagnosis to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival: median 16.8 months (95% CI 10.3 to 22.6) (Ab3 responders vs non‐responders 18.2 vs 13.1, P = 0.0896; HAMA responders vs non‐responders 22.6 months vs 7.6 months, P = 0.0016); overall survival: median 34.4 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival and 3‐year survival: Ab3 responders vs non‐responders 22.9 vs 13.5 months, P = 0.0089, 38% vs 8%; T‐cell responders vs non‐responders (n = 16) &gt; 84 vs 13.2 months, P = 0.0202, 75% vs 0% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival: 19.4 months, Ab3 responders vs non‐responders: 23.4 vs 4.9 months, P &lt; 0.0001 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression: 4 months (95% CI 3 to 5 months)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recurrence‐free survival (randomisation to recurrence)/overall survival (randomisation to death) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median recurrence‐free survival: abagovomab 403 days (95% CI 323 to 414) vs placebo 402 days (95% CI 323 to 487) </p> <p>2‐year overall survival rate: abagovomab 80% (SE 1.71) vs placebo 80% (SE 2.43)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival (diagnosis to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: robust Ab3 responders vs non‐robust responders 49 vs 38 months, P = 0.0029; Ab2 robust vs non‐robust responders 30.0 vs 44.0 months, P = 0.0475 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not described separately for ovarian cancer patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (first dose to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival: 22.0 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not described</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival: robust Ab2 vs non‐robust Ab2 responders: NS</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>Ab2: anti‐idiotype antibody.<br/> Ab3: anti‐anti‐idiotype antibody.<br/> CI: confidence interval.<br/> HAMA: human‐anti‐mouse antibody.<br/> HR: hazard ratio.<br/> SE: standard error. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Definitions and results of survival and/or relapse analysis in antigen‐specific antibody studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Definitions and results of survival and/or relapse analysis in other antigen‐specific immunotherapy studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Definition</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Results</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recurrence rate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>recurrence rate: n = 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (study day 0 to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression &gt; 8 months (range 4 to &gt; 9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival (first vaccination to relapse)/overall survival (first vaccination to death/last follow‐up) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3‐year progression‐free survival: arm 1 vs arm 2, 40% vs 80% (P = 0.17)</p> <p>3‐year overall survival: arm 1 vs arm 2, 80% vs 100% (P = 1.00) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (last chemo to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression 13.0 months (95% CI 11.2 to not reached)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: time from start of therapy until progression in weeks</p> <p>overall survival: time from start of therapy until death in weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Progression‐free survival cohort 3: 8 to 36 (median 13)</p> <p>Overall survival cohort 3: 12 to 48 (median 37)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free interval; survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free interval: 4 months (95% CI 1.9 to 7.6)</p> <p>median survival: 13.3. months (95% CI 1.5 to 30.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: 12.2 months (range 1.3 to 38.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival; overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival vaccine vs standard of care 365 days vs 321 days</p> <p>overall survival: not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival</p> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: 13 months (Cvac) vs 9 months (standard of care)</p> <p>overall survival: median not reached at 43 months in both study arms.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival; overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: 9, 18, 19+ months; OS: 6, 19+, 21 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (first vaccination to relapse)/overall survival (first vaccination to death) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time overall (n = 42): 19.1 months</p> <p>median survival time platinum‐sensitive (n = 17): 39.3 months</p> <p>median survival time platinum‐resistant (n = 25): 16.2 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time from first vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival time 14.5 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>disease‐specific survival (diagnosis to death of ovarian cancer)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median disease‐specific survival participants vs historical controls: 44.0 months vs 47.4 months </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survival (trial entry to death)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median survival: 12.7 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: 2 months (range 1 to 36)</p> <p>median overall survival: 15.5 months (range 1.5 to &gt; 57.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: not reached (range 289 to 1115+ days)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: time from the end of adjuvant chemotherapy until disease progression </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not adequately described</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (first vaccination to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 19.0 months (95% CI 9.0 to not reached)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: 21 months (95% CI 16 to 29 months)</p> <p>median overall survival: 48 months (95% CI not estimable)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 14.0 (range 12.1 to 18.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival (date on study to date of progression)</p> <p>overall survival (date on study to date of death or last follow‐up)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median progression‐free survival: 4.2 vs 8.7 months</p> <p>median overall survival: 40.8 vs 29.6 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (trial entry to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 6 months (range 2 to 17)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression (first vaccination to relapse)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median time to progression: 4.2 months (95% CI 2.7 to 8.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no differences between cohorts (numbers not reported)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: time from randomisation to first clinical, biochemical, or radiological evidence of progression </p> <p>overall survival: time from study untill death.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>progression‐free survival: 5.9 months vaccine + OPT‐821 vs 6.5 months OPT‐821 only</p> <p>overall survival: 46.5 months vaccine + OPT‐821 vs 46.2 months OPT‐821 only</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time to progression/overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>time of progression: not reported</p> <p>overall survival after 12 months of all patients: 20.6%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall survival</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>median overall survival: HLA‐A24 5 months (range 30 to 623 days), HLA‐A02 9 months (range 54 to 921 days) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI: confidence interval.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Definitions and results of survival and/or relapse analysis in other antigen‐specific immunotherapy studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Definitions and results of anti‐idiotypic (Ab2) humoral responses in antigen‐specific monoclonal antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Robust if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% robust</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 g</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94% vs 74%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐50‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13% vs 31% vs 67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 250 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0 μ/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 10 μ/L</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32%</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Definitions and results of anti‐idiotypic (Ab2) humoral responses in antigen‐specific monoclonal antibody studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Definitions and results of anti‐anti‐idiotypic (Ab3) humoral responses in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Robust if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% robust</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes; reported in <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐50‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.015 μg/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L vs S: 100% vs 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 μ/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1000 μ/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>placebo: stable</p> <p>abagovomab: increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Definitions and results of anti‐anti‐idiotypic (Ab3) humoral responses in antigen‐specific antibody studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Definitions and results of humoral response evaluation in other antigen‐specific immunotherapy studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assay</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1 ± ErbB1 ± CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>topoisomerase IIα, integrin β8 subunit precursor, ABI‐binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBP, Her‐2/Neu, MAGE‐A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, hTERT, PADRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2× pretreatment and &gt; mean + 2 SD of 10 normal sera</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CYP1B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>No response measured</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TERT, survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>high response: &gt; 0.6</p> <p>intermediate response: 0.2 to 0.6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60% high responses, 40% intermediate responses</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>personalised (max 4 out of 31 vacinne candidates)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Luminex assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 out of 4 vaccine‐specific IgG titers is 2‐fold higher than pre‐vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 vaccinations: 16/42</p> <p>12 vaccinations: 29/30</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1 ± MUC1 ± CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mesothelin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pre‐imm: 40%, post‐imm: 45%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomsen Friedenreich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80% IgA, 90% IgM, 90% IgG, 0% IgE</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1, CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I, toposiomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Tn, TF, sTN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IgM titer &gt; 1:80 or at least 4‐fold increase from baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IgM: GM2 25%, Globo‐H 8%, Tn 58%, TF 67%, sTn 92%</p> <p>IgG: GM2 17%, Globo‐H 58%, Tn 83%, TF 25%, sTN 67%</p> <p>20/24 responded to at least 3 antigens</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>reciprocal titer &gt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 patients remained seropositive</p> <p>5/6 became seropositive</p> <p>no differences between cohorts.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lewis Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Lewis Y, Tn‐MUC1, Tn(c), sTN(c), TF(c)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>negative to ≥ 1:40 or 8‐fold increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89% ≥ 3 antigens; 22% GM2, 33% Globo‐H, 11% Lewis Y, 100% Tn‐MUC1, 44% Tn(c), 44% sTN(c), 78% TF(c) </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cohort 1: 25%, C2: 46%, C3: 91%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, MUC1‐TN, TF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1:40 or 2‐fold increase</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IgG: GLOBO‐H 7%, GM2 8%, MUC1‐TN 32%, MUC1 45%, TF 13%</p> <p>IgM: GLOBO‐H 21%, GM2 26%, MUC1‐TN 40%, MUC1 49%, TF 22%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1:20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% IgM, 80% IgG</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GPC3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>optical density cutoff value 0.47</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HLA‐A24: FOXM1, MELK, HJURP, VEGFR1, VEGFR2</p> <p>HLA‐A02: HIG2, VEGFR1, VEGFR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patient‐tailored cocktail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>SD: standard deviation.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Definitions and results of humoral response evaluation in other antigen‐specific immunotherapy studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Definitions and results of cellular responses in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assay</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>permutation test </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44% vs 21% </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>flow cytometry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patients with a CA‐125‐CTL count above 0.410 × 10^6 (=90th percentile level of CA‐125‐specific CTL count in the placebo arm) for at least 1 of the time points throughout the study </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31.8% (treatment arm) vs 26.3% (placebo arm)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>permutation test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4 CA‐125: 75%; n = 3 oregovomab 67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>permutation test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 18 CA‐125: 39%; n = 8 oregovomab 50%; n = 8 autologous tumour cells 63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐5‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4: 50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay/ cytokine ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay: Wilcoxon signed rank test; cytokine ELISA: unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 17 CA‐125 53%; Th1 cytokines 41%, Th2 cytokines 94%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cytokine flow cytometry</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2‐fold increase in IFN‐γ‐expressing T‐cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L vs S: n = 12 vs 17, CD4: 58% vs 29%; CD8 75% vs 18%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>spots experimental wells ‐ control wells &gt; 20 and experimental wells/control wells &gt; 1.5× </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 5: 80%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ secretion assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM n = 1 (100%)</p> <p>Her‐2/Neu n = 1 (0%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>leucocyte migration inhibition assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>CTL: cytotoxic T‐cell.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Definitions and results of cellular responses in antigen‐specific antibody studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0012"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Definitions and results of cellular responses in other antigen‐specific immunotherapy studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen(s)</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Assay</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0001" title="AntonilliM , RahimiH , ViscontiV , NapoletanoC , RuscitoI , ZizzariIG , et al. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: clinical and immunological data of a phase I/II clinical trial. International Journal of Oncology2016;48:1369‐78. [PUBMED: 26892612] ">Antonilli 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1 ± ErbB1 ± CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ ELISPOT</p> <p>delayed hypersensitvity test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: 2‐fold increase in IFN‐γ production</p> <p>Delayed hypersensitvity test: unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: 6/7 + 0/3</p> <p>Delayed hypersensitvity test: 3/7</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0006" title="BerinsteinNL , KarkadaM , MorseMM , NemunaitisJJ , ChattaG , KaufmanH , et al. First‐in‐man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi‐functional T cell responses in ovarian, breast and prostate cancer. Journal of Translational Medicine2012;10:156. ">Berinstein 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>topoisomerase IIα, integrin β8 subunit precursor, ABI‐binding protein C3, TACE/ADAM17, junction plakglobin, EDDR1, BAP31 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>pentamer staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2× increase in pentamer‐positive CD8‐cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83% against at least 1 peptide</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0007" title="BerinsteinNL , OzaAM , OdunsiK , KarkadaM , VillellaJA , NemunaitisJJ , et al. Effect of oral cyclophosphamide on the immunogenicity of DPX‐Survivac in ovarian cancer patients: results of a phase I study. American Society of Clinical Oncology Annual Meeting. 2013. ">Berinstein 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>tetramer staining</p> <p>intracellular cytokine staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>combined results cohort 2 + 3: 92% on ≥ 2 assays</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0009" title="BrossartP , WirthsS , StuhlerG , ReichardtVL , KanzL , BruggerW . Induction of cytotoxic T‐lymphocyte responses in vivo after vaccinations with peptide‐pulsed dendritic cells. Blood2000;96(9):3102‐8. ">Brossart 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intracellular IFN‐γ staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 1: Her‐2/Neu 100%; n = 2: MUC1 50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0011" title="Chianese‐BullockKA , IrvinWP , PetroniGR , MurphyC , SmolkinM , OlsonWC , et al. A multipeptide vaccine is safe and elicits T‐cell responses in participants with advanced stage ovarian cancer. Journal of Immunotherapy2008;31(4):420‐30. ">Chianese‐Bullock 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>FBP, Her‐2/Neu, MAGE‐A1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 9: FBP 40%, Her‐2/Neu 83%, MAGE‐A1 83%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0012" title="ChuCS , BoyerJ , CoukosG , RubinSC , MorganMA , BendigDL , et al. Autologous dendritic cell (IDD‐6) vaccination as consolidation for advanced ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2008. ChuCS , BoyerJ , SchulleryDS , GimottyPH , GamermanV , BenderJ , et al. Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission. Cancer Immunology Immunotherapy2012;61:629‐41. ">Chu 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu, hTERT, PADRE</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>tetramer staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>hTERT: cohort 1: 100%, cohort 2: 100%</p> <p>Her‐2/Neu: cohort 1: 60%, cohort 2: 0%</p> <p>PADRE: cohort 1: 60%, cohort 2: 60%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0014" title="DiefenbachCSM , GnjaticS , SabbatiniP , AghajanianC , HensleyML , SpriggsDR , et al. Safety and immunogenicity study of NY‐ESO‐1b peptide and montanide ISA‐51 vaccination of patients with epithelial ovarian cancer in high‐risk first remission. Clinical Cancer Research2008;14(9):2740‐8. ">Diefenbach 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>intracellular cytokine staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0015" title="DijkgraafEM , SantegoetsSJ , ReynersAK , GoedemansR , NijmanHW , vanPoelgeestMI , et al. A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum‐resistant ovarian cancer. Oncotarget2015;6:32228‐43. [PUBMED: 26334096] ">Dijkgraaf 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Cohort 3: gemcitabine, PegIntron, and p53 SLP vaccine</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3‐fold change compared to baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cohort 3: 6/6</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0013" title="DhodapkarM , ZhaoB , WangD , LutzkyRD , CarvajalRD , KeohanM , et al. A phase I trial of a novel vaccine targeting NY‐ESO‐1 to the dendritic cell receptor DEC‐205 in combination with toll‐like receptor agonists. Society for Immunotherapy of Cancer Annual Meeting. 2012. ">Dhodapkar 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT/Tetramer staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots &gt; 30 and &gt; 3× spots irrelevant control &gt; 0.1% tetramer‐positive CD8‐cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>both assays n = 9: 67%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0017" title="FreedmanRS , KudelkaAP , VerschraegenCF , EdwardsCL , TomasovicB , KaplanA , et al. Therapeutic anti‐cancer vaccine: a randomized double blind dose comparison study of sialyl Tn‐KLH with Detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1998. TermrungruanglertW , KudelkaAP , VerschraegenCF , FreedmanRS , EdwardsCL , TomasovicB , et al. Therapeutic anticancer vaccine: a randomized double blind dose comparison study of sialyl TN‐K with detox‐B SE adjuvant for active specific immunotherapy of ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 1996. ">Freedman 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0018" title="GalanisE , HartmannL , ClibyWA , LongHJ , PeethambaramPP , BarretteBA , et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Research2010;70(3):875‐82. ">Galanis 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0019" title="GohJ , CAN‐003 Study Team, GargoskySE , GrayH . Clinical study of autologous dendritic cell therapy targeting mucin 1 for treatment of ovarian cancer patients in first remission. European Cancer Congress. 2013. ">Goh 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0021" title="GrayHJ , BenignoB , BerekJ , ChangJ , MasonJ , MileshkinL , et al. Progression‐free and overall survival in ovarian cancer patients treated with CVac, a mucin 1 dendritic cell therapy in a randomized phase 2 trial. Journal for Immunotherapy of Cancer2016;4:34. [PUBMED: 27330807] ">Gray 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intracellular cytokine staining (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inadequately reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0022" title="GribbenJG , RyanDP , UrbanRG , HedleyML , BeachK , NealonP , et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clinical Cancer Research2005;11(12):4430‐6. ">Gribben 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CYP1B1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>spots minus negative control &gt; 20/10⁶ PBMC and &gt; 2× baseline</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 5: 20%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0023" title="GulleyJL , ArlenPM , TsangKY , YokokawaJ , PalenaC , PooleDJ , et al. Pilot study of vaccination with recombinant CEA‐MUC‐1‐TRICOM poxviral‐based vaccines in patients with metastatic carcinoma. Clinical Cancer Research2008;14:3060‐9. ">Gulley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CEA, MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)/IFN‐γ ELISA (CD4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: ≥ 2‐fold increase in IFN‐γ‐secreting cells</p> <p>IFN‐γ ELISA: unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 3: 100% CEA</p> <p>n = 3: 33% CEA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0025" title="ImhoffM , LipovacM , Angleitner‐BoubenizekL , BartaJ , GomezI , HrdinaA , et al. Double‐loaded mature dendritic cell (DC) therapy for non‐HLA‐restricted patients with advanced ovarian cancer: final results of a clinical phase I study. American Society of Clinical Oncolocy Annual Meeting. 2013. ">Imhof 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>TERT, survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>intracellular cytokine staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>overall &gt; 90%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0026" title="KaumayaPTP , FoyKC , GarrettJ , RawaleSV , VicariD , ThurmondJM , et al. Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, b‐cell epitopes fused to a promiscuous T‐cell epitope in patients with metastatic and/or recurrent solid tumors. Journal of Clinical Oncology2009;27(31):5270‐7. ">Kaumaya 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0027" title="KawanoK , TsudaN , MatsuedaS , SasadaT , WatanabeN , UshijimaK , et al. Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients. Immunopharmacology Immunotoxicology2014;36:224‐36. [PUBMED: 24773550] ">Kawano 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>personalised (max 4 out of 31 vaccine candidates)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2‐fold higher values post‐vaccination than pre‐vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6 vaccinations: 18/42</p> <p>12 vaccinations: 19/42</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0028" title="KobayashiM , ChibaA , IzawaH , YanagidaE , OkamotoM , ShimodairaS , et al. The feasibility and clinical effects of dendritic cell‐based immunotherapy targeting synthesized peptides for recurrent ovarian cancer. Journal of Ovarian Research2014;7:48. [PUBMED: 25298213] ">Kobayashi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1 ± MUC1 ± CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Flow cytometry (CD4/CD8/NK)</p> <p>Tetramer staining (WT‐1 CTLs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>flow cytometry: no chances in CD4+, CD8+, and NK cell frequency</p> <p>tetramer staining: 12/17 increased</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0029" title="LeDT , BrockstedtDG , Nir‐PazR , HamplJ , MathurS , NemunaitisJ , et al. A live‐attenuated listeria vaccine (ANZ‐100) and a live‐attenuated listeria vaccine expressing mesothelin (CRS‐207) for advanced cancers: phase I studies of safety and immune induction. Clinical Cancer Research2012;18(3):858‐68. ">Le 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mesothelin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots &gt; 2× baseline and ≥ 1 per 10⁵ PBMC</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 1 evaluable, mesothelin‐specific CD8 cells present</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0030" title="LeffersN , LambeckAJ , GoodenMJ , HoogeboomBN , WolfR , HammingIE , et al. Immunization with a P53 synthetic long peptide vaccine induces P53‐specific immune responses in ovarian cancer patients, a phase II trial. International Journal of Cancer2009;May 28:[Epub ahead of print]. LeffersN , VermeijR , HoogeboomBN , SchultzeUR , WolfR , HammingIE , et al. Long‐term clinical and immunological effects of p53‐SLP vaccine in patients with ovarian cancer. International Journal of Cancer2012;130:105‐12. ">Leffers 2009a</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>proliferation assay</p> <p>intracellular cytokine staining (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots ≥ 10/10⁵ PBMC and ≥ 3× pre‐immunisation</p> <p>cpm &gt; 1000/min, SI ≥ 3, and ≥ 2× pre‐immunisation</p> <p>≥ 3 pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 18: 100%</p> <p>n = 17: 82%</p> <p>n = 5: CD8 0%, CD4 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0031" title="LennerzV , GrossS , GalleraniE , SessaC , MachN , BoehmS , et al. Immunologic response to the survivin‐derived multi‐epitope vaccine EMD640744 in patients with advanced solid tumors. Cancer Immunology Immunotherapy2014;63:381‐94. [PUBMED: 24487961] ">Lennerz 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>survivin</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT/HLA‐multimer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8): spot number &gt; 10 and 2‐fold higher than background and 2‐fold higher than standard deviation of all combined negative values </p> <p>HLA‐multimer staining: detection of &gt; 50 cells in the multimer gate, minimum percentage of 0.03% CD8+ cells </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ex vivo ELISPOT: n = 0/7</p> <p>in vivo ELISPOT: n = 1/2</p> <p>ex vivo multimer: n = 2/5</p> <p>in vivo multimer: n = 3/4</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0032" title="LetschA , ScheibenbogenC , AsemissenAM , ZimmermannK , KnodlerM , Völker‐CallM , et al. Wilms tumor protein (WT) 1 peptide vaccination in patients with WT1 expressing solid tumors demonstrates clinical and immunological efficacy. Onkologie2011;34(Suppl 6):194. ">Letsch 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>tetramer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0035" title="MacLeanGD , ReddishMA , KogantyRR , LongeneckerBM . Antibodies against mucin‐associated sialyl‐Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. Journal of Immunotherapy With Emphasis on Tumor Immunology1996;19(1):59‐68. ">MacLean 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0034" title="MacLeanGD , Bowen‐YacyshynMB , SamuelJ , MeikleA , StuartG , NationJ , et al. Active immunization of human ovarian cancer patients against a common carcinoma (Thomsen‐Friedenreich) determinant using a synthetic carbohydrate antigen. Journal of Immunotherapy1992;11(4):292‐305. ">MacLean 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Thomsen Friedenreich</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0038" title="MohebtashM , MadanR , TsangK , ArlenPh , PazdurM , JonesJ , et al. Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer. American Association of Cancer Research Annual Meeting. 2009. MohebtashM , TsangKY , HuenNY , PooleDJ , JochemsC , JonesJ , et al. A pilot study of MUC‐1/CEA/TRICOM poxviral‐based vaccine in patients with metastatic breast and ovarian cancer. Clinical Cancer Research2011;17(22):7164‐73. ">Mohebtash 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1, CEA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2× pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2: 0%; MUC1‐specific CD8 cells 50%, CEA‐specific CD8 cells</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0039" title="MorseMA , SecordAA , BlackwellK , HobeikaAM , SinnathambyG , OsadaT , et al. MHC class I‐presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T‐cell responses against breast and ovarian cancer. Clinical Cancer Research2011;17(10):3408‐19. ">Morse 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>APC, HHR6A, BAP31, replication protein A, Abl‐binding protein 3c, cyclin I, toposiomerase IIα/β, integrin β 8 subunit precursor, CDC2, TACE, g‐catenin, EEDDR1 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 40 spots/10⁶ PBMC over pre‐vaccination</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 8: 63%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0041" title="NishikawaH , QianF , TsujiT , RitterG , OldLJ , GnjaticS , et al. Influence of CD4(+)CD25(+) regulatory T cells on low/high‐avidity CD4(+) T cells following peptide vaccination. Journal of Immunology2006;176(10):6340‐6. ">Nishikawa 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4: 75%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0043" title="O'CearbhaillRE , RagupathiG , ZhuJ , WanQ , MironovS , YangG , et al. A phase I study of unimolecular pentavalent (Globo‐H‐GM2‐sTn‐TF‐Tn) immunization of patients with epithelial ovarian, fallopian tube, or peritoneal cancer in first remission. Cancers2016;8:46. [PUBMED: 27110823] ">O'Cearbhaill 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Tn, TF, sTN</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0044" title="OdunsiK , QianF , MatsuzakiJ , Mhawech‐FaucegliaP , AndrewsC , HoffmanEW , et al. Vaccination with an NY‐ESO‐1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proceedings of the National Academy of Sciences of the United States of America2007;104(31):12837‐42. ">Odunsi 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>mean ± 3 SD</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 18; CD4: 83%, CD8: 33%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0045" title="OdunsiK , MatsuzakiJ , KarbachJ , NeumannA , Mhawech‐FaucegliaP , MillerM , et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY‐ESO‐1 antigen in ovarian cancer and melanoma patients. PNAS2012;109(15):5797‐802. OdunsiK , RodabaughK , LeleS , OldLJ , MatsuzakiJ , QianF , et al. Diversified prime and boost vaccination using recombinant vaccinia and fowlpox expressing NY‐ESO‐1 efficiently induces antibody, CD4+, and CD8+ antitumor immune responses in patients with ovarian cancer. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2007. ">Odunsi 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> <p>intracellular cytokine staining (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD4: 91%</p> <p>CD8: 45%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0046" title="OdunsiK , MatsuzakiJ , JamesSR , Mhawech‐FaucegliaP , TsujiT , MillerA , et al. Epigenetic potentiation of NY‐ESO‐1 vaccine therapy in human ovarian cancer. Cancer Immunology, Immunotherapy2014;2:37‐49. [24535937] ">Odunsi 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> <p>tetramer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT: spot numbers in the presence of target cells exceeded cutoff value (&gt; 50 spots/50,000 cells) + at least 3 times more spots than unpulsed target cells </p> <p>tetramer: &gt; 0.1% tetramer‐positive cells are CD8+ T‐cells and at least 3 times more than the percentage obtained with control tetramer. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD8: 5/11 (45%), of which 3 de novo inductions</p> <p>CD4: 7/10 (70%), of which 2 de novo responses</p> <p>tetramer staining: 2× NY‐ESO‐1 CD8 cell expansion</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0047" title="DohiS , OhnoS , OhnoY , TakakuraM , KyoS , SomaGI , et al. WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report. Anticancer Research2001;31:2441‐6. OhnoS , KyoS , MyojoS , DohiS , IshizakiJ , MiyamotoKI , et al. Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy. Anticancer Research2009;29:4779‐84. ">Ohno 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>WT1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0048" title="PeethambaramPP , MeliskoME , RinnKJ , AlbertsSR , ProvostNM , JonesLA , et al. A phase I trial of immunotherapy with Lapuleucel‐T (APC8024) in patients with refractory metastatic tumors that express Her‐2/neu. Clinical Cancer Research2009;15(18):5937‐44. ">Peethambaram 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Her‐2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay</p> <p>ELISPOT assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported separately for ovarian cancer patients</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0050" title="HerrinV , AchtarM , SteinbergS , WhitesideTL , WieckowskE , CzystowskaM , et al. A randomized phase II p53 vaccine trial comparing subcutaneous direct administration with intravenous peptide‐pulsed dendritic cells in high risk ovarian cancer patients. American Society of Clinical Oncology Annual Meeting. 2007. HerrinV , BehrensRJ , AchtarM , MonahanB , BernsteinS , Brent‐SteeleT , et al. Wild‐type p53 peptide vaccine can generate a specific immune response in low burden ovarian adenocarcinom. American Society of Clinical Oncology Annual Meeting. 2003. RahmaOE , AshtarE , CzystowskaM , SzajnikME , WieckowskiE , BernsteinS , et al. A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients. Cancer Immunology, Immunotherapy2012;61:374‐84. ">Rahma 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>tetramer staining</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 2× pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>cohort 1: 64%, cohort 2: 83%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0052" title="SabbatiniPJ , KudryashovV , RagupathiG , DanishefskySJ , LivingstonPO , BornmannW , et al. Immunization of ovarian cancer patients with a synthetic Lewis(y)‐protein conjugate vaccine: a phase 1 trial. Clinical Cancer Research2000;87(1):79‐85. ">Sabbatini 2000</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Lewis Y</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0054" title="SabbatiniPJ , RagupathiG , HoodC , AghajanianCA , JuretzkaM , IasonosA , et al. Pilot study of a heptavalent vaccine‐keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clinical Cancer Research2007;13:4170‐7. ">Sabbatini 2007</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GM2, Globo‐H, Lewis Y, Tn‐MUC1, Tn(c), sTN(c), TF(c)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0055" title="SabbatiniP , TsujiT , FerranL , RitterE , SedrakC , TuballesK , et al. Phase I trial of overlapping long peptides from a tumor self‐antigen and poly‐ICLC shows rapid induction of integrated immune response in ovarian cancer patients. Clinical Cancer Research2012;18(23):6497‐508. ">Sabbatini 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50 spots/5 × 10⁴ cells and &gt; 3× unstimulated cells</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD4: 100% in cohort 1, 2, and 3</p> <p>CD8: cohort 1: 0%, cohort 2: 62%, cohort 3: 92%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0057" title="SabbatiniP , ChenL , LucciJ , BehbakhtK , SpirtosN , MullerC . OPT‐821 with or without vaccine therapy in treating patients with ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer in second or third complete remission. clinicaltrials.gov2017. [NCT00857545] ">Sabbatini 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>171</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Globo‐H, GM2, MUC1‐TN, TF</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0058" title="SandmaierBM , OparinDV , HolmbergLA , ReddishMA , MacLeanGD , LongeneckerBM . Evidence of a cellular immune response against sialyl‐Tn in breast and ovarian cancer patients after high‐dose chemotherapy, stem cell rescue, and immunization with Theratope STn‐KLH cancer vaccine. Journal of Immunotherapy1999;22(1):54‐66. ">Sandmaier 1999</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Sialyl‐Tn</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>proliferation assay<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; upper limit of normal (SI 2.35)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 4: 50%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0061" title="SuzukiS , SakataJ , UtsumiF , SekiyaR , KajiyamaH , ShibataK , et al. Efficacy of glypican‐3‐derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma. Oncoimmunology2016;5(11):1238542. [PUBMED: 27999758] ">Suzuki 2016</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>GPC3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT (CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 15/24: 62.5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0062" title="TakeokaT , NagaseH , KuroseK , OhueY , YamasakiM , TakiguchiS , et al. NY‐ESO‐1 protein cancer vaccine with Poly‐ICLC and OK‐432: rapid and strong induction of NY‐ESO‐1‐specific immune responses by Poly‐ICLC. Journal of Immunotherapy2017;40:140‐7. [PUBMED: 28338507] ">Takeoka 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NY‐ESO‐I</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ catch assay (CD4/CD8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 0.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CD4: n = 2; &gt; 5%</p> <p>CD8: n = 2; 1% to 5%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0063" title="TakeuchiS , ShojiT , KagabuM , HondaT , MiuraF , OmiH , et al. A phase I/II study of multiple peptides cocktail vaccine for advanced/recurrent ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2013. ">Takeuchi 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>HLA‐A24: FOXM1, MELK, HJURP, VEGFR1, VEGFR2</p> <p>HLA‐A02: HIG2, VEGFR1, VEGFR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inadequately reported</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0064" title="TsudaN , MochizukiK , HaradaM , SukehiroA , KawanoK , YamadaA , et al. Vaccination with predesignated or evidence‐based peptides for patients with recurrent gynecologic cancers. Journal of Immunotherapy2004;27(1):60‐72. ">Tsuda 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>patient‐tailored cocktail</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>IFN‐γ ELISA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n = 2 after 6 vacc 100%; n = 1 after 12 vacc 100%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0066" title="VermeijR , LeffersN , HoogeboomBN , HammingLE , WolfR , ReynersAKL , et al. Potentiation of a p53‐SLP vaccine by cyclophosphamide in ovarian cancer: a single‐arm phase II study. International Journal of Cancer2012;131:E670‐80. ">Vermeij 2012</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>p53</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>ELISPOT</p> <p>proliferation assay</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>specific spots ≥ 10/10⁵ PBMC and ≥ 3× pre‐immunisation</p> <p>cpm &gt; 1000/min, SI ≥ 3, and ≥ 2× pre‐immunisation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90% after 2 vacc, 87.5% after 4 vacc</p> <p>80% after 2 vacc, 62.5% after 4 vacc</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>as measured after at least three immunisations. <br/> C1: cohort 1.<br/> SD: standard deviation.<br/> SI: stimulation index. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Definitions and results of cellular responses in other antigen‐specific immunotherapy studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007287-tbl-0013"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Definitions and results of human‐anti‐mouse antibody (HAMA) evaluation in antigen‐specific antibody studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>N</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Dose</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Target antigen</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Analysed</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Positive if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% positive</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Robust if:</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>% robust</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0002" title="BaumannK , PfistererJ , WimbergerP , BurchardiP , KurzederC , du BoisA , et al. Intraperitoneal treatment with the trifunctional bispecific antibody catumaxomab in patients with platinum‐resistant epithelial ovarian cancer: a phase IIa study of the AGO Study Group. Gynecologic Oncology2011;123:27‐32. ">Baumann 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 10‐10‐10‐10 μg</p> <p>C2: 10‐20‐50‐100 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>C1: 61%, C2: 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0003" title="BerekJS , EhlenTG , GordonA , NicodemusCF , SchultesB , WhitesideTL , et al. Interim analysis of a double blind study of Ovared mAb B43.13 (OV) versus placebo (PBO) in patients with ovarian cancer. American Society of Clinical Oncology Annual Meeting. 2001. ">Berek 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0004" title="BerekJS , TaylorPT , GordonA , CunninghamMJ , FinklerN , OrrJ , et al. Randomized, placebo‐controlled study of oregovomab for consolidation of clinical remission in patients with advanced ovarian cancer. Journal of Clinical Oncology2004;22(17):3507‐16. BerekJS , TaylorPT , NicodemusCF . CA125 velocity at relapse is a highly significant predictor of survival post relapse: results of a 5‐year follow‐up survey to a randomized placebo‐controlled study of maintenance oregovomab immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2008;31(2):207‐14. ">Berek 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0005" title="BerekJ , TaylorP , McGuireW , SmithLM , SchultesB , NicodemusCF . Oregovomab maintenance monoimmunotherapy does not improve outcome in advanced ovarian cancer. Journal of Clinical Oncology2009;27:418‐25. BerekJ , TaylorPT , McGuireWP , SmithLM , SchultesB , NicodemusCF . Evaluation of maintenance mono‐immunotherapy to improve outcomes in advanced ovarian cancer (OV CA). ASCO Annual Meeting. 2008. ">Berek 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>371</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.r.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0008" title="BralyP , ChuC , CollinsY , EdwardsR , GordonA , McGuireW , et al. Prospective evaluation of front‐line chemo‐immunotherapy (C‐IT) with oregovomab (2 alternative dosing schedules) carboplatin‐paclitaxel (C‐P) in advanced ovarian cancer (OC). American Society of Clinical Oncology Annual Meeting. 2007. BralyP , NicodemusCF , ChuC , CollinsY , EdwardsR , GordonA , et al. The immune adjuvant properties of front‐line carboplatin‐paclitaxel: a randomised phase 2 study of alternative schedules of intravenous oregovomab chemo‐immunotherapy in advanced ovarian cancer. Journal of Immunotherapy2009;32:54‐65. MethodM , GordonA , SmithLM , NicodemusCF . Oregovomab immune‐modulating antibody therapy concurrent to standard chemotherapy of epithelial ovarian cancer (EOC): feasibility and initial clinical experience. Society of Gynecologic Oncologists Annual Meeting on Women's Cancer. 2006. ">Braly 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIM vs OWD: 100% vs 80%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SIM vs OWD: 88% vs 74%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0010" title="BuzzonettiA , FossatiM , CatzolaV , ScambiaG , FattorossiA , BattagliaA . Immunological response induced by abagovomab as a maintenance therapy in patients with epithelial ovarian cancer: relationship with survival ‐ a substudy of the MIMOSA trial. Cancer Immunology Immunotherapy2014;63:1037‐45. [PUBMED: 24952307] ">Buzzonetti 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes; reported in <a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0016" title="EhlenTG , HoskinsPJ , MillerD , WhitesideTL , NicodemusCF , SchultesBC , et al. A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer. International Journal of Gynecological Cancer2005;15(6):1023‐34. ">Ehlen 2005</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0020" title="GordonAN , SchultesBC , GallionH , EdwardsR , WhitesideTL , CermakJM , et al. CA125‐ and tumor‐specific T‐cell responses correlate with prolonged survival in oregovomab‐treated recurrent ovarian cancer patients. Gynecologic Oncology2004;94(2):340‐51. ">Gordon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0024" title="HeissMM , MaruwaP , KoralewskiP , KutarskaE , KolesnikOO , IvanchenkoVV , et al. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial. International Journal of Cancer2010;127:2209‐21. ">Heiss 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10‐20‐50‐150 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0033" title="MaJ , ZhouL , WangD . Functional mimicry of an anti‐idiotypic antibody to nominal antigen on cellular response. Japanese Journal of Cancer Research2002;93(1):78‐84. ">Ma 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0036" title="MethodM , GordonA , FinklerN , FingertH , NicodemusCF , WhitesideTL , et al. Randomized evaluation of 3 treatment schedules to optimize clinical activity of OvaRex Mab B43.13 (OV) in patients (pts) with epithelial ovarian cancer (EOC). American Society of Clinical Oncology Annual Meeting. 2002. ">Method 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4% vs 36% vs 39%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0037" title="MobusVJ , BaumRP , BolleM , KreienbergR , NoujaimAA , SchultesBC , et al. Immune responses to murine monoclonal antibody‐B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. American Journal of Obstetrics and Gynecology2003;189(1):28‐36. ">Möbus 2003</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 5000 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0040" title="NicholsonS , BomphrayCC , ThomasH , McIndoeA , BartonD , GoreM , et al. A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer. Cancer Immunology, Immunotherapy2004;53(9):809‐16. ">Nicholson 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>MUC1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0042" title="NoujaimAA , SchultesBC , BaumRP , MadiyalakanR . Induction of CA125‐specific B and T cell responses in patients injected with MAb‐B43.13 ‐ evidence for antibody‐mediated antigen‐processing and presentation of CA125 in vivo. Cancer Biotherapy &amp; Radiopharmaceuticals2001;16(3):187‐203. ">Noujaim 2001</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg       </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0049" title="PfistererJ , du BoisA , SehouliJ , LoiblS , ReinartzS , ReussA , et al. The anti‐idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO‐OVAR. Annals of Oncology2006;17(10):1568‐77. ">Pfisterer 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 15 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>L vs S: 94% vs 100%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0051" title="ReinartzS , KohlerS , SchlebuschH , KristaK , GiffelsP , RenkeK , et al. Vaccination of patients with advanced ovarian carcinoma with the anti‐idiotype ACA125: immunological response and survival (phase Ib/II). Clinical Cancer Research2004;10(5):1580‐7. WagnerU , KohlerS , ReinartzS , GiffelsP , HuoberJ , RenkeK , et al. Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti‐idiotype antibody ACA125: immune responses and survival in palliative treatment. Clinical Cancer Research2001;7(5):1154‐62. ">Reinartz 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0053" title="SabbatiniP , DupontJ , AghajanianC , DerosaF , PoynorE , AndersonS , et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clinical Cancer Research2006;12(18):5503‐10. ">Sabbatini 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg/0.2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0056" title="SabbatiniP , HartherP , ScambiaG , SehouliJ , MeierW , WimbergerP , et al. Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO and GEICO ‐ the MIMOSA study. Journal of Clinical Oncology2013;31(12):1554‐61. ">Sabbatini 2013</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>888</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>inadequately reported</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0059" title="SchultesB , YangR , AgopsowiczK , KuzmaM , DharampaulS , BaumR , et al. Anti‐idiotype induction therapy for ovarian cancer: immune responses in patients injected with OvaRex‐Mab‐B43.13. American Society of Clinical Oncology Annual Meeting. 1999. SchultesBC , BaumRP , NiesenA , NoujaimAA , MadiyalakanR . Anti‐idiotype induction therapy: anti‐CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1). Cancer Immunology, Immunotherapy1998;46(4):201‐12. ">Schultes 1998</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 mg      </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 200 ng/mL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0060" title="StröhleinMA , SiegelR , JägerM , LindhoferH , JauchKW , HeissMM . Induction of anti‐tumor immunity by trifunctional antibodies in patients with peritoneal carcinomatosis. Journal of Experimental &amp; Clinical Cancer Research2009;28:18. ">Ströhlein 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10/20/40 μg</p> <p>10/40/80 μg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>EpCAM</p> <p>Her2/Neu</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>unknown</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100% (n = 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0065" title="vanZanten‐PrzybyszI , MolthoffC , GebbinckJK , vonMensdorff‐PouillyS , VerstraetenR , KenemansP , et al. Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study. Journal of Cancer Research and Clinical Oncology2002;128(9):484‐92. ">van Zanten‐Przybysz 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50 mg     </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>membrane folate receptor</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>n.a.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD007287-bbs2-0067" title="WagnerU . Antitumor antibodies for immunotherapy of ovarian carcinomas. Hybridoma1993;12(5):521‐8. WagnerU , ReinsbergJ , SchmidtS , MallmannP , SchmollingJ , SchultesB , et al. Monoclonal antibodies and idiotypic network activation for ovarian carcinoma. Cell Biophysics1994;24‐25:237‐42. ">Wagner 1993</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1 mg</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CA‐125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>n.r.: not reported.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Definitions and results of human‐anti‐mouse antibody (HAMA) evaluation in antigen‐specific antibody studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007287.pub4/full#CD007287-tbl-0013">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007287.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD007287-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD007287-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007287-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD007287-note-0004">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD007287-note-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ko#CD007287-note-0006">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007287-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD007287-note-0002">繁體中文</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD007287-note-0022">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007287\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007287\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007287\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007287\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007287\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007287.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007287.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007287.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007287.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007287.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728526517"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007287.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728526521"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007287.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec6916f01f431',t:'MTc0MDcyODUyNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 